1
|
Buske C, Dreyling M, Alvarez-Larrán A, Apperley J, Arcaini L, Besson C, Bullinger L, Corradini P, Giovanni Della Porta M, Dimopoulos M, D'Sa S, Eich HT, Foà R, Ghia P, da Silva MG, Gribben J, Hajek R, Harrison C, Heuser M, Kiesewetter B, Kiladjian JJ, Kröger N, Moreau P, Passweg JR, Peyvandi F, Rea D, Ribera JM, Robak T, San-Miguel JF, Santini V, Sanz G, Sonneveld P, von Lilienfeld-Toal M, Wendtner C, Pentheroudakis G, Passamonti F. Managing hematological cancer patients during the COVID-19 pandemic: an ESMO-EHA Interdisciplinary Expert Consensus. ESMO Open 2022; 7:100403. [PMID: 35272130 PMCID: PMC8795783 DOI: 10.1016/j.esmoop.2022.100403] [Citation(s) in RCA: 25] [Impact Index Per Article: 12.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/20/2021] [Revised: 01/13/2022] [Accepted: 01/18/2022] [Indexed: 12/15/2022] Open
Abstract
BACKGROUND The COVID-19 pandemic has created enormous challenges for the clinical management of patients with hematological malignancies (HMs), raising questions about the optimal care of this patient group. METHODS This consensus manuscript aims at discussing clinical evidence and providing expert advice on statements related to the management of HMs in the COVID-19 pandemic. For this purpose, an international consortium was established including a steering committee, which prepared six working packages addressing significant clinical questions from the COVID-19 diagnosis, treatment, and mitigation strategies to specific HMs management in the pandemic. During a virtual consensus meeting, including global experts and lead by the European Society for Medical Oncology and the European Hematology Association, statements were discussed and voted upon. When a consensus could not be reached, the panel revised statements to develop consensual clinical guidance. RESULTS AND CONCLUSION The expert panel agreed on 33 statements, reflecting a consensus, which will guide clinical decision making for patients with hematological neoplasms during the COVID-19 pandemic.
Collapse
Affiliation(s)
- C Buske
- Institute of Experimental Cancer Research, Department of Internal Medicine III, University Hospital Ulm, Ulm, Germany.
| | - M Dreyling
- Department of Medicine III at LMU Hospital, Munich, Germany
| | - A Alvarez-Larrán
- Hematology Department, Hospital Clínic, IDIBAPS, Barcelona, Spain
| | - J Apperley
- Centre for Haematology, Imperial College London, Hammersmith Hospital, London, UK
| | - L Arcaini
- Division of Hematology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; Department of Molecular Medicine, University of Pavia, Pavia, Italy
| | - C Besson
- Service d'Hématologie Oncologie, Centre Hospitalier de Versailles, Le Chesnay, France; UVSQ, Inserm, CESP, Villejuif, France
| | - L Bullinger
- Department of Hematology, Oncology, and Tumorimmunology, Campus Virchow Klinikum, Berlin, Germany; Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
| | - P Corradini
- Hematology Division, University of Milan, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy
| | - M Giovanni Della Porta
- Cancer Center, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy; Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy
| | - M Dimopoulos
- Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece
| | - S D'Sa
- UCLH Centre for Waldenström and Neurohaematology, University College London Hospitals NHS Foundation Trust, London, UK
| | - H T Eich
- Department of Radiation Oncology, University of Muenster, Münster, Germany
| | - R Foà
- Hematology, Department of Translational and Precision Medicine, Sapienza University, Rome, Italy
| | - P Ghia
- Strategic Research Program on Chronic Lymphocytic Leukemia and Laboratory of B Cell Neoplasia, Division of Molecular Oncology, Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Milan, Italy
| | - M G da Silva
- Department Of Hematology, Portuguese Institute of Oncology, Lisbon, Portugal
| | - J Gribben
- Barts Cancer Institute, Queen Mary University of London, London, UK
| | - R Hajek
- Department of Hematooncology, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic
| | - C Harrison
- Clinical Director - Haematology, Haemostasis, Palliative Care, Cellular Pathology, Guy's and St Thomas' NHS Foundation Trust, London, UK
| | - M Heuser
- Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hanover, Germany
| | - B Kiesewetter
- Department of Medicine I, Division of Oncology, Medical University of Vienna, Vienna, Austria
| | - J J Kiladjian
- Université de Paris, APHP, Hôpital Saint-Louis, Centre d'Investigations Cliniques, Paris, France
| | - N Kröger
- Department of Stem Cell Transplantation, University Hospital Hamburg-Eppendorf, Hamburg, Germany
| | - P Moreau
- Hematology Department, University Hospital Hotel-Dieu, Nantes, France
| | - J R Passweg
- Hematology Division, Basel University Hospital, Basel, Switzerland
| | - F Peyvandi
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milan, Italy; Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy
| | - D Rea
- University Medical Department of Hematology and Immunology, France Intergroupe des Leucémies Myéloïdes Chroniques (Fi-LMC), Hôpital Saint-Louis, Paris, France
| | - J-M Ribera
- Clinical Hematology Department, ICO-Hospital Germans Trias i Pujol, Josep Carreras Research Institute, Universitat Autònoma de Barcelona, Badalona, Spain
| | - T Robak
- Department of Hematology, Medical University of Lodz, Lodz, Poland
| | - J F San-Miguel
- Clínica Universidad de Navarra (CUN), Centro de Investigación Aplicada (CIMA), Instituto de Investigación Sanitaria de Navarra (IDISNA), CIBERONC, Pamplona, Spain
| | - V Santini
- MDS Unit, Hematology, DMSC, AOUC, University of Florence, Florence, Italy
| | - G Sanz
- Hematology Department, Hospital Univesitario y Politecnico La Fe, Valencia; CIBERONC, IS Carlos III, Madrid, Spain
| | - P Sonneveld
- Erasmus MC Cancer Institute, Department of Haematology, Rotterdam, The Netherlands
| | - M von Lilienfeld-Toal
- Department of Hematology and Medical Oncology, University Hospital Jena, Jena, Germany; Leibniz Institute for Natural Product Research and Infection Biology, Hans Knöll Institute, Jena, Germany
| | - C Wendtner
- Munich Clinic Schwabing, Academic Teaching Hospital, Ludwig-Maximilian University, Munich, Germany
| | - G Pentheroudakis
- Scientific and Medical Division, European Society for Medical Oncology, Lugano, Switzerland
| | - F Passamonti
- Department of Medicine and Surgery, University of Insubria, Varese, Italy.
| |
Collapse
|
2
|
Hadi I, Schummer A, Dreyling M, Eze C, Bodensohn R, Roengvoraphoj O, Belka C, Li M. Effectiveness and tolerability of radiotherapy for patients with indolent non-Hodgkin's lymphoma: a monocenter analysis. Sci Rep 2021; 11:22586. [PMID: 34799601 PMCID: PMC8604980 DOI: 10.1038/s41598-021-01851-w] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/01/2021] [Accepted: 10/26/2021] [Indexed: 12/30/2022] Open
Abstract
To analyze the effectiveness and toxicities of radiotherapy in indolent non-Hodgkin's lymphoma (iNHL) patients treated in our institution. Patients with iNHL treated with radiotherapy between 1999 and 2016 were included. The primary endpoint was progression-free survival (PFS). Secondary endpoints were local control (LC), overall survival (OS) and toxicities. PFS, LC, and OS were analyzed using Kaplan-Meier method. Log-rank test was used to investigate the differences between subgroups. Cox proportional hazard model was used for univariate continuous analysis. Seventy-five patients were identified in our institutional database between 1999 and 2016. Fifty-eight (77.3%) had stage I after Ann-Arbor and 17 patients (22.7%) had stage II. The median follow-up was 87 months (95% CI 72-102 months). Median single dose per fraction was 2.0 Gy (range 1.5-2 Gy) and median total dose was 30.6 Gy (range 16-45 Gy). Radiotherapy was performed in 2D (n = 10; 13.3%), 3D (n = 63; 84.0%) and VMAT (n = 2; 2.7%) techniques, respectively. The median PFS was 14.0 years (95% CI 8.3-19.7 years). The estimated PFS after 5 and 10 years were 73.0% and 65.5% in Kaplan-Meier analysis, respectively. The 5- and 10-year LC were 94.9% and 92.3%, respectively. The 5- and 10-year OS were 88.6% and 73.9%. In univariate analyses of PFS, younger patients (≤ 60 years old) had significantly superior PFS to those older than 60 years old (5-year PFS 81.9% vs. 65.1%, p = 0.021). Dose escalation > 36.0 Gy had no prognostic influence in term of PFS (p = 0.425). Extranodal involvement, stage and histology had no prognostic impact on PFS. Depending on the site of lymphomas, the most common acute side effects were: dermatitis CTCAE° I-II (8.0%), xerostomia CTC° I (8.0%), cataract CTC° I (12.0%) and dry eyes CTC° I-II (14.6%). No adverse event CTC° III was reported. Most acute side effects recovered at 3 to 6 months after radiotherapy except for CTC° I cataract and xerostomia. Local Radiotherapy was highly effective for treatment of early stage iNHL with no serious side effects in our cohort. The most acute CTCAE° I-II side effects recovered 3 to 6 months later. Technique advances seem to have further improved effectiveness and tolerability of radiotherapy.Trial registration: Local ethics committee of Ludwig-Maximilian-University (LMU) Munich approved this retrospective analysis on the May 7th, 2019 (Nr. 19-137).
Collapse
Affiliation(s)
- I Hadi
- Department of Radiation Oncology, University Hospital, LMU Munich, 81377, Munich, Germany
| | - A Schummer
- Department of Radiation Oncology, University Hospital, LMU Munich, 81377, Munich, Germany
| | - M Dreyling
- Department of Internal Medicine III - Oncology, University Hospital, LMU Munich, Munich, Germany
| | - C Eze
- Department of Radiation Oncology, University Hospital, LMU Munich, 81377, Munich, Germany
| | - R Bodensohn
- Department of Radiation Oncology, University Hospital, LMU Munich, 81377, Munich, Germany
| | | | - C Belka
- Department of Radiation Oncology, University Hospital, LMU Munich, 81377, Munich, Germany.,German Cancer Consortium DKTK, Munich, Germany
| | - M Li
- Department of Radiation Oncology, University Hospital, LMU Munich, 81377, Munich, Germany.
| |
Collapse
|
3
|
Hadi I, Hartoyo S, Bodensohn R, Dreyling M, Niyazi M, Belka C, Li M. PO-1081 Effectiveness and tolerability of radiotherapy for patients with diffuse large cell B-cell lymphoma. Radiother Oncol 2021. [DOI: 10.1016/s0167-8140(21)07532-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
4
|
Schuster SJ, Dickinson M, Dreyling M, Martinez‐Lopez J, Kolstad A, Butler J, Ghosh M, Popplewell L, Chavez JC, Bachy E, Kato K, Harigae H, Kersten MJ, Andreadis C, Riedell PA, Abdelhady A, Zia A, Morisse MC, Fowler NH, Thieblemont C. EFFICACY AND SAFETY OF TISAGENLECLEUCEL (TISA‐CEL) IN ADULT PATIENTS (PTS) WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (R/R FL): PRIMARY ANALYSIS OF THE PHASE 2 ELARA TRIAL. Hematol Oncol 2021. [DOI: 10.1002/hon.85_2879] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- S. J. Schuster
- Perelman Center for Advanced Medicine University of Pennsylvania Philadelphia USA
| | - M. Dickinson
- Clinical Haematology Peter MacCallum Cancer Centre and Royal Melbourne Hospital Melbourne Australia
| | - M. Dreyling
- Medizinische Klinik III, LMU Klinikum Munich Germany
| | - J. Martinez‐Lopez
- Hospital 12 De Octubre Madrid Complutense University CNIO Madrid Spain
| | - A. Kolstad
- Department of Oncology Oslo University Hospital Oslo Norway
| | - J. Butler
- Haematology and Bone Marrow Transplantation Royal Brisbane Hospital Herston Australia
| | - M. Ghosh
- Department of Internal Medicine Michigan Medicine University of Michigan Ann Arbor USA
| | - L. Popplewell
- Department of Hematology & Hematopoietic Cell Transplantation City of Hope National Medical Center Duarte USA
| | - J. C. Chavez
- Department of Malignant Hematology Moffitt Cancer Center Tampa USA
| | - E. Bachy
- Department of Hematology Hospices Civils de Lyon and Université Claude Bernard Lyon 1 Lyon France
| | - K. Kato
- Department of Hematology Kyushu University Hospital Fukuoka Japan
| | - H. Harigae
- Department of Hematology Tohoku University Hospital Sendai Japan
| | - M. José Kersten
- Cancer Center Amsterdam Amsterdam UMC University of Amsterdam on behalf of HOVON/LLPC Amsterdam Netherlands
| | - C. Andreadis
- Helen Diller Family Comprehensive Cancer Center University of California San Francisco San Francisco USA
| | - P. A. Riedell
- Department of Medicine University of Chicago Chicago USA
| | - A. Abdelhady
- Oncology Novartis Pharmaceuticals Corporation East Hanover USA
| | - A. Zia
- Biostatistics Novartis Pharma AG Basel Switzerland
| | - M. C. Morisse
- Oncology Novartis Pharmaceuticals Corporation East Hanover USA
| | - N. H. Fowler
- MD Anderson Cancer Center The University of Texas MD Anderson Cancer Center Houston Texas USA
| | - C. Thieblemont
- Department of Hemato‐Oncology Hôpital Saint‐Louis‐Université de Paris Paris France
| |
Collapse
|
5
|
Novak U, Fehr M, Schär S, Dreyling M, Scheubeck G, Ramadan S, Zucca E, Zander T, Hess G, Mey U, Ferrero S, Mach N, Boccomini C, Böttcher S, Voegeli M, Cairoli A, Menter T, Dirnhofer S, Gadient S, Eckhardt K, Driessen C, Renner C. SAKK 36/13 ‐ IBRUTINIB PLUS BORTEZOMIB AND IBRUTINIB MAINTENANCE FOR RELAPSED AND REFRACTORY MANTLE CELL LYMPHOMA: FINAL REPORT OF A PHASE I/II TRIAL OF THE EUROPEAN MCL NETWORK. Hematol Oncol 2021. [DOI: 10.1002/hon.62_2879] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- U. Novak
- Inselspital, Bern University Hospital Medical Oncology Bern Switzerland
| | - M. Fehr
- Kantonsspital St. Gallen Department of Medical Oncology and Hematology St. Gallen Switzerland
| | - S. Schär
- SAKK Coordinating Center Bern Switzerland
| | - M. Dreyling
- Universität München‐Grossadern Medizinische Klinik III München Germany
| | - G. Scheubeck
- Universität München‐Grossadern Medizinische Klinik III München Germany
| | - S. Ramadan
- IEO, European Institute of Oncology IRCCS Onco‐Hematology Division Milano Italy
| | - E. Zucca
- Oncology Institute of Southern Switzerland Ospedale San Giovanni Bellinzona Switzerland
| | - T. Zander
- Kantonsspital Luzern Department Oncology Luzern Switzerland
| | - G. Hess
- Johannes Gutenberg Universität Mainz Universitätsmedizin Mainz Germany
| | - U. Mey
- Kantonsspital Graubünden Department of Oncology and Hematology Chur Switzerland
| | - S. Ferrero
- AOU "Città della Salute e della Scienza di Torino" Hematology 1 Torino Italy
| | - N. Mach
- University Hospital of Geneva Department of Oncology Genève Switzerland
| | - C. Boccomini
- AOU "Città della Salute e della Scienza di Torino" Hematology 1 Torino Italy
| | - S. Böttcher
- Rostock University Medical Center Department of Medicine, Clinic III ‐ Hematology, Oncology Palliative Medicine Rostock Germany
| | - M. Voegeli
- Kantonsspital Baselland Oncology Liestal Switzerland
| | - A. Cairoli
- CHUV University Hospital and University of Lausanne Service et Laboratoire Central d'Hématologie Département d'Oncologie Lausanne Switzerland
| | - T. Menter
- University Hospital Basel Institute of Pathology and Medical Genetics Basel Switzerland
| | - S. Dirnhofer
- University Hospital Basel Institute of Pathology and Medical Genetics Basel Switzerland
| | - S. Gadient
- SAKK Coordinating Center Bern Switzerland
| | | | - C. Driessen
- Kantonsspital St. Gallen Department of Medical Oncology and Hematology St. Gallen Switzerland
| | - C. Renner
- Onkozentrum, Hirslanden & Zürich Zürich Switzerland
| |
Collapse
|
6
|
Fowler NH, Dickinson M, Martinez‐Lopez J, Kolstad A, Schuster SJ, Dreyling M, Ghosh M, Harigae H, Kersten MJ, Bachy E, Popplewell L, Chavez JC, Ho PJ, Butler J, Kato K, Tresckow B, Ferreri AJM, Simón JAP, Patten PEM, Andreadis C, Riedell PA, McGuirk JP, Nastoupil LJ, Teshima T, Offner F, Petzer A, Viardot A, Zinzani PL, Malladi R, Zhang J, Tiwari R, Bollu V, Masood A, Thieblemont C. PATIENT‐REPORTED QUALITY OF LIFE (QOL) FOLLOWING TISAGENLECLEUCEL (TISA‐CEL) INFUSION IN ADULT PATIENTS (PTS) WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (R/R FL). Hematol Oncol 2021. [DOI: 10.1002/hon.178_2880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- N. H. Fowler
- The University of Texas MD Anderson Cancer Center Department of Lymphoma‐Myeloma Houston Texas USA
| | - M. Dickinson
- Royal Melbourne Hospital Peter MacCallum Cancer Centre Melbourne Australia
| | | | - A. Kolstad
- Oslo University Hospital Department of Oncology Oslo Norway
| | - S. J. Schuster
- University of Pennsylvania Lymphoma Program Philadelphia Pennsylvania USA
| | - M. Dreyling
- LMU Klinikum Medizinische Klinik III Munich Germany
| | - M. Ghosh
- University of Michigan Michigan Medicine Ann Arbor Michigan USA
| | - H. Harigae
- Tohoku University Hospital Department of Hematology and Rheumatology Sendai Japan
| | - M. José Kersten
- Amsterdam UMC University of Amsterdam on behalf of HOVON/LLPC Department of Hematology Amsterdam Netherlands
| | - E. Bachy
- Université Claude Bernard Lyon 1 Hospices Civils de Lyon Lyon France
| | - L. Popplewell
- City of Hope National Medical Center Department of Hematology & Hematopoietic Cell Transplantation Duarte California USA
| | - J. C. Chavez
- Moffitt Cancer Center Department of Malignant Hematology Tampa Florida USA
| | - P. J. Ho
- Royal Prince Alfred Hospital and University of Sydney Institute of Haematology Camperdown Australia
| | - J. Butler
- Royal Brisbane Hospital Haematology and Bone Marrow Transplant Unit Herston Australia
| | - K. Kato
- Kyushu University Hospital Hematology, Oncology, & Cardiovascular Medicine Fukuoka Japan
| | - B. Tresckow
- University Hospital Essen University of Duisburg‐Essen Clinic for Hematology and Stem Cell Transplantation West German Cancer Center Essen Germany
| | - A. J. M. Ferreri
- IRCCS Ospedale San Raffaele Department of Onco‐hematology Milan Italy
| | - J. A. P. Simón
- University Hospital Virgen del Rocío Instituto de Biomedicina de Sevilla (IBIS / CSIC / CIBERONC) Universidad de Sevilla Department of Hematology Sevilla Spain
| | - P. E. M. Patten
- King’s College Hospital and King’s College London Division of Cancer Studies London UK
| | - C. Andreadis
- University of California San Francisco Helen Diller Family Comprehensive Cancer Center San Francisco California USA
| | - P. A. Riedell
- University of Chicago Medical Center Department of Medicine Chicago Illinois USA
| | - J. P. McGuirk
- University of Kansas Medical Center Division of Hematologic Malignancies and Cellular Therapeutics Kansas City Kansas USA
| | - L. J. Nastoupil
- The University of Texas MD Anderson Cancer Center Department of Lymphoma‐Myeloma Houston Texas USA
| | - T. Teshima
- Hokkaido University Hospital Department of Hematology Sapporo Japan
| | - F. Offner
- UZ Gent Department of Hematology Gent Belgium
| | - A. Petzer
- Ordensklinikum Linz GmbH Elisabethinen Internal Medicine I Linz Austria
| | - A. Viardot
- University Hospital of Ulm Department of Internal Medicine III Ulm Germany
| | - P. L. Zinzani
- University of Bologna Institute of Hematology “Seràgnoli” Bologna Italy
| | - R. Malladi
- Cambridge University Hospitals NHS Foundation Trust Centre for Clinical Haematology Cambridge UK
| | - J. Zhang
- Novartis Pharmaceuticals Corporation Global Value and Access East Hanover New Jersey USA
| | - R. Tiwari
- Novartis Healthcare Pvt. Ltd Biostatistics Hyderabad India
| | - V. Bollu
- Novartis Pharmaceuticals Corporation Health Economics and Outcomes Research East Hanover New Jersey USA
| | - A. Masood
- Novartis Pharmaceuticals Corporation Clinical Development East Hanover New Jersey USA
| | - C. Thieblemont
- Hôpital Saint‐Louis‐Université de Paris Service d'Hématologie‐Oncologie Paris France
| |
Collapse
|
7
|
Rejeski K, Perez A, Sesques P, Berger C, Jentzsch L, Mougiakakos D, Frölich L, Ackermann J, Bücklein V, Blumenberg V, Schmidt C, Jallades L, Fehse B, Faul C, Karschnia P, Weigert O, Dreyling M, Hoster E, Locke F, Bergwelt‐Baildon M, Mackensen A, Bethge W, Ayuk F, Bachy E, Salles G, Jain M, Subklewe M. CAR‐HEMATOTOX: A DISCRIMINATIVE MODEL FOR CAR T‐CELL RELATED HEMATOTOXICITY IN RELAPSED/REFRACTORY LARGE B‐CELL LYMPHOMA. Hematol Oncol 2021. [DOI: 10.1002/hon.82_2879] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- K. Rejeski
- University Hospital of the LMU Munich Department of Hematology/Oncology Munich Germany
| | - A. Perez
- Moffitt Cancer Center Department of Blood and Marrow Transplant and Cellular Immunotherapy Moffitt Cancer Center, Tampa, USA Tampa USA
| | - P. Sesques
- Hospices Civils de Lyon Institut National de la Santé et de la Recherche Médicale (INSERM) Lyon France
| | - C. Berger
- University Hospital Hamburg‐Eppendorf Department of Hematology, Oncology and Pulmonology Hamburg Germany
| | - L. Jentzsch
- University Hospital Tübingen Department of Hematology, Oncology, Immunology and Rheumatology Tübingen Germany
| | - D. Mougiakakos
- University Hospital of Erlangen Department of Internal Medicine 5, Hematology and Oncology Erlangen Germany
| | - L. Frölich
- University Hospital of the LMU Munich Department of Hematology/Oncology Munich Germany
| | - J. Ackermann
- University Hospital of the LMU Munich Department of Hematology/Oncology Munich Germany
| | - V. Bücklein
- University Hospital of the LMU Munich Department of Hematology/Oncology Munich Germany
| | - V. Blumenberg
- University Hospital of the LMU Munich Department of Hematology/Oncology Munich Germany
| | - C. Schmidt
- University Hospital of the LMU Munich Department of Hematology/Oncology Munich Germany
| | - L. Jallades
- Hospices Civils de Lyon Institut National de la Santé et de la Recherche Médicale (INSERM) Lyon France
| | - B. Fehse
- University Hospital Hamburg‐Eppendorf Department of Hematology, Oncology and Pulmonology Hamburg Germany
| | - C. Faul
- University Hospital Tübingen Department of Hematology, Oncology, Immunology and Rheumatology Tübingen Germany
| | - P. Karschnia
- University Hospital of the LMU Munich Department of Neurosurgery Munich Germany
| | - O. Weigert
- University Hospital of the LMU Munich Department of Hematology/Oncology Munich Germany
| | - M. Dreyling
- University Hospital of the LMU Munich Department of Hematology/Oncology Munich Germany
| | - E. Hoster
- LMU Munich Institute for Medical Informatics Biometry and Epidemiology Munich Germany
| | - F. Locke
- Moffitt Cancer Center Department of Blood and Marrow Transplant and Cellular Immunotherapy Moffitt Cancer Center, Tampa, USA Tampa USA
| | - M. Bergwelt‐Baildon
- University Hospital of the LMU Munich Department of Hematology/Oncology Munich Germany
| | - A. Mackensen
- University Hospital of Erlangen Department of Internal Medicine 5, Hematology and Oncology Erlangen Germany
| | - W. Bethge
- University Hospital Tübingen Department of Hematology, Oncology, Immunology and Rheumatology Tübingen Germany
| | - F. Ayuk
- University Hospital Hamburg‐Eppendorf Department of Hematology, Oncology and Pulmonology Hamburg Germany
| | - E. Bachy
- Hospices Civils de Lyon Institut National de la Santé et de la Recherche Médicale (INSERM) Lyon France
| | - G. Salles
- MSKCC, Lymphoma Service Department of Medicine NYC New York USA
| | - M. Jain
- Moffitt Cancer Center Department of Blood and Marrow Transplant and Cellular Immunotherapy Moffitt Cancer Center, Tampa, USA Tampa USA
| | - M. Subklewe
- University Hospital of the LMU Munich Department of Hematology/Oncology Munich Germany
| |
Collapse
|
8
|
Duell J, Maddocks KJ, González‐Barca E, Jurczak W, Liberati AM, Obr A, Gaidano G, Abrisqueta P, André M, Dreyling M, Menne T, Dirnberger‐Hertweck M, Weirather J, Ambarkhane S, Salles G. LONG‐TERM ANALYSES FROM L‐MIND, A PHASE II STUDY OF TAFASITAMAB PLUS LENALIDOMIDE (LEN) IN PATIENTS (PTS) WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA (R/R DLBCL). Hematol Oncol 2021. [DOI: 10.1002/hon.28_2879] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- J Duell
- Universitätsklinik Würzburg, Medizinische Klinik und Poliklinik II Würzburg Germany
| | - K. J Maddocks
- Arthur G James Comprehensive Cancer Center Ohio State University Wexner Medical Center Department of Internal Medicine Columbus USA
| | - E González‐Barca
- Institut Catalá d’Oncologia (ICO) Hospital Duran i Reynals, IDIBELL, Universitat de Barcelona Department of Hematology Barcelona Spain
| | - W Jurczak
- Maria Sklodowska‐Curie National Research Institute of Oncology Department of Clinical Oncology Kraków Poland
| | - A. M Liberati
- Azienda Ospedaliera Santa Maria di Terni Università degli Studi di Perugia Terni Italy
| | - A Obr
- Palacký University and University Hospital Olomouc Department of Hemato‐Oncology Olomouc Czech Republic
| | - G Gaidano
- University of Piemonte Orientale Amedeo Avogadro Division of Hematology Department of Translational Medicine Novara Italy
| | - P Abrisqueta
- Vall d’Hebron Institute of Oncology (VHIO) Vall d’Hebron University Hospital Department of Hematology Barcelona Spain
| | - M André
- Université Catholique de Louvain CHU UCL Namur Department of Haematology Yvoir Belgium
| | - M Dreyling
- University Hospital Ludwig‐Maximilians Munich Germany
| | - T Menne
- Freeman Hospital Newcastle Upon Tyne Hospitals NHS Foundation Trust Department of Haematology Newcastle Upon Tyne UK
| | | | | | - S Ambarkhane
- MorphoSys AG Clinical Development Planegg Germany
| | - G Salles
- Hospices Civils de Lyon and Université de Lyon Hématologie Lyon France
| |
Collapse
|
9
|
Villa D, Hoster E, Hermine O, Klapper W, Szymczyk M, Bosly A, Unterhalt M, Freeman CL, Scott DW, Gerrie AS, Savage KJ, Sehn LH, Dreyling M. RITUXIMAB IN COMBINATION WITH BENDAMUSTINE OR HIGH‐DOSE CYTARABINE‐BASED INDUCTION THERAPY IN TRANSPLANT‐ELIGIBLE PATIENTS WITH MANTLE CELL LYMPHOMA. Hematol Oncol 2021. [DOI: 10.1002/hon.62_2880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- D. Villa
- BC Cancer, Centre for Lymphoid Cancer Vancouver Canada
| | - E. Hoster
- Ludwig‐Maximilians‐Universität München Institute for Medical Information Processing, Biometry, and Epidemiology Munich Germany
| | - O. Hermine
- University of Paris Descartes, Hôpital Necker Assistance Publique Hôpitaux de Paris Paris France
| | - W. Klapper
- Universitätsklinikum Schleswig‐Holstein Institut für Pathologie, Sektion Hämatopathologie und Lymphknotenregister Kiel Germany
| | - M. Szymczyk
- Maria Sklodowska‐Curie National Research Institute of Oncology Department of Lymphoid Malignancies Warsaw Poland
| | - A. Bosly
- CHU UCL Mont‐Godinne‐Dinant Faculty of Medicine and Dentistry Yvoir Belgium
| | - M. Unterhalt
- University of Ulm Department of Internal Medicine Ulm Germany
| | - C. L. Freeman
- BC Cancer, Centre for Lymphoid Cancer Vancouver Canada
| | - D. W. Scott
- BC Cancer, Centre for Lymphoid Cancer Vancouver Canada
| | - A. S. Gerrie
- BC Cancer, Centre for Lymphoid Cancer Vancouver Canada
| | - K. J. Savage
- BC Cancer, Centre for Lymphoid Cancer Vancouver Canada
| | - L. H. Sehn
- BC Cancer, Centre for Lymphoid Cancer Vancouver Canada
| | - M. Dreyling
- Ludwig‐Maximilians‐Universität München Medizinische Klinik III Munich Germany
| |
Collapse
|
10
|
Dreyling M, Ghielmini M, Rule S, Salles G, Ladetto M, Tonino SH, Herfarth K, Seymour JF, Jerkeman M. Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2021; 32:298-308. [PMID: 33249059 DOI: 10.1016/j.annonc.2020.11.008] [Citation(s) in RCA: 97] [Impact Index Per Article: 32.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/01/2020] [Revised: 11/10/2020] [Accepted: 11/10/2020] [Indexed: 12/25/2022] Open
Affiliation(s)
- M Dreyling
- Department of Medicine III, LMU Hospital Munich, Germany
| | - M Ghielmini
- Oncology Institute of Southern Switzerland, Ospedale San Giovanni, Bellinzona, Switzerland
| | - S Rule
- Haematology, Peninsula School of Medicine, Plymouth, UK
| | - G Salles
- Service d'Hématologie, Hospices Civils de Lyon, Centre Hospitalier Lyon-Sud, Lyon; Université Claude Bernard Lyon-1, Pierre-Benite, France
| | - M Ladetto
- Divisione di Ematologia, Azienda Ospedaliera Santi Antonio e Biagio e Cesare Arrigo, Alessandria, Italy
| | - S H Tonino
- Department of Hematology, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands
| | - K Herfarth
- Department of Radiation Oncology, University of Heidelberg, Germany
| | - J F Seymour
- Department of Haematology, Peter McCallum Cancer Center & Royal Melbourne Hospital, Melbourne, University of Melbourne, Parkville, Australia
| | - M Jerkeman
- Department of Oncology, Skåne University Hospital, Lund University, Lund, Sweden
| |
Collapse
|
11
|
Fürstenau M, Bahlo J, Fink AM, Lange E, Dreger P, Dreyling M, Hess G, Ritgen M, Kneba M, Döhner H, Stilgenbauer S, Wendtner CM, Goede V, Fischer K, Böttcher S, Hallek M, Eichhorst B. Residual abdominal lymphadenopathy after intensive frontline chemoimmunotherapy is associated with inferior outcome independently of minimal residual disease status in chronic lymphocytic leukemia. Leukemia 2019; 34:924-928. [PMID: 31611627 DOI: 10.1038/s41375-019-0597-3] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/18/2019] [Revised: 08/30/2019] [Accepted: 09/30/2019] [Indexed: 11/10/2022]
Affiliation(s)
- M Fürstenau
- Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German CLL Study Group, University Hospital Cologne, University of Cologne, Cologne, Germany.
| | - J Bahlo
- Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German CLL Study Group, University Hospital Cologne, University of Cologne, Cologne, Germany
| | - A M Fink
- Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German CLL Study Group, University Hospital Cologne, University of Cologne, Cologne, Germany
| | - E Lange
- Evangelisches Krankenhaus Hamm, Hamm, Germany
| | - P Dreger
- Department of Medicine V, University Hospital Heidelberg, Heidelberg, Germany
| | - M Dreyling
- Department of Internal Medicine III, University Hospital of the Ludwig Maximilians University Munich, Munich, Germany
| | - G Hess
- Department of Hematology, Medical Oncology and Pneumology, University Medical Center of the Johannes Gutenberg-University, Mainz, Germany
| | - M Ritgen
- Department II of Internal Medicine, University of Schleswig-Holstein, Kiel, Germany
| | - M Kneba
- Department II of Internal Medicine, University of Schleswig-Holstein, Kiel, Germany
| | - H Döhner
- Department of Internal Medicine III, University Hospital Ulm, Ulm, Germany
| | - S Stilgenbauer
- Department of Internal Medicine III, University Hospital Ulm, Ulm, Germany.,Department of Hematology, Oncology and Rheumatology and José Carreras Center for Immuno and Gene Therapy, Saarland University Medical School, Homburg/Saar, Germany
| | - C M Wendtner
- Department of Hematology, Oncology, Immunology, Palliative Care, Infectious Diseases and Tropical Medicine, München Klinik Schwabing, Munich, Germany
| | - V Goede
- Oncogeriatric Unit, Department of Geriatric Medicine, St. Marien Hospital, Cologne, Germany
| | - K Fischer
- Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German CLL Study Group, University Hospital Cologne, University of Cologne, Cologne, Germany
| | - S Böttcher
- Department II of Internal Medicine, University of Schleswig-Holstein, Kiel, Germany.,Medical Clinic III, Hematology, Oncology and Palliative Medicine, Rostock University Medical Center, Rostock, Germany
| | - M Hallek
- Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German CLL Study Group, University Hospital Cologne, University of Cologne, Cologne, Germany.,Cologne Cluster of Excellence in Cellular Stress Responses in Aging-associated Disease (CECAD), University of Cologne, Cologne, Germany
| | - B Eichhorst
- Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German CLL Study Group, University Hospital Cologne, University of Cologne, Cologne, Germany.
| |
Collapse
|
12
|
Salles G, Duell J, González Barca E, Jurczak W, Liberati A, Nagy Z, Obr A, Gaidano G, Andre M, Kalakonda N, Dreyling M, Zinzani P, Dirnberger-Hertweck M, Weirather J, Ambarkhane S, Maddocks K. PRIMARY ANALYSIS RESULTS OF THE SINGLE-ARM PHASE II STUDY OF MOR208 PLUS LENALIDOMIDE IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (L-MIND). Hematol Oncol 2019. [DOI: 10.1002/hon.130_2629] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- G. Salles
- Hospices Civils de Lyon; Centre Hospitalier Lyon Sud, Service d'Hématologie; Pierre-Bénite France
| | - J. Duell
- Medizinische Klinik und Poliklinik II; University Hospital of Würzburg; Würzburg Germany
| | - E. González Barca
- Department of Hematology; Institut Catalá d'Oncología, Hospital Duran i Reynals, IDIBELL; Barcelona Spain
| | - W. Jurczak
- Department of Hematology; Jagiellonian University; Kraków Poland
| | - A.M. Liberati
- SC Oncoematologia; Azienda Ospedaliera Santa Maria; Terni Italy
| | - Z. Nagy
- First Department of Internal Medicine; Semmelweis University; Budapest Hungary
| | - A. Obr
- Department of Hemato-Oncology; Palacký University Olomouc and the University Hospital Olomouc; Olomouc Czech Republic
| | - G. Gaidano
- Division of Haematology; Department of Translational Medicine, University of Eastern Piedmont; Novara Italy
| | - M. Andre
- Department of Hematology; Université catholique de Louvain, CHU UCL Namur; Yvoir Belgium
| | - N. Kalakonda
- Department of Haemato-oncology; Clatterbridge Cancer Centre and University of Liverpool; Wirral United Kingdom
| | - M. Dreyling
- Department of Medicine III; University Hospital of Ludwig-Maximilians-Universität; Munich Germany
| | - P.L. Zinzani
- Institute of Hematology “L. e A. Seràgnoli”; University of Bologna; Bologna Italy
| | | | - J. Weirather
- Department of Biostatistics and Data Management; MorphoSys AG; Planneg Germany
| | - S. Ambarkhane
- Department of Clinical Development; MorphoSys AG; Planegg Germany
| | - K. Maddocks
- Department of Internal Medicine; Division of Hematology, The Ohio State University Comprehensive Cancer Center; Columbus Ohio United States
| |
Collapse
|
13
|
Zoellner A, Unterhalt M, Stilgenbauer S, Hübel K, Thieblemont C, Metzner B, Kluin-Nelemans H, Hiddemann W, Dreyling M, Hoster E. AUTOLOGOUS STEM CELL TRANSPLANTATION IN FIRST REMISSION SIGNIFICANTLY PROLONGS PROGRESSION-FREE AND OVERALL SURVIVAL IN MANTLE CELL LYMPHOMA. Hematol Oncol 2019. [DOI: 10.1002/hon.13_2629] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Affiliation(s)
- A. Zoellner
- Department of Medicine III; University Hospital; LMU Munich Munich Germany
| | - M. Unterhalt
- Department of Medicine III; University Hospital; LMU Munich Munich Germany
| | - S. Stilgenbauer
- Department of Internal Medicine I; University Hospital of Homburg; Homburg Germany
| | - K. Hübel
- Department of Medicine I; University Hospital of Cologne; Cologne Germany
| | - C. Thieblemont
- Hemato-Oncology Department; Diderot University; Hôpital Saint-Louis Paris France
| | - B. Metzner
- Department of Hematology/Oncology; University Hospital Oldenburg; Oldenburg Germany
| | | | - W. Hiddemann
- Department of Medicine III; University Hospital; LMU Munich Munich Germany
| | - M. Dreyling
- Department of Medicine III; University Hospital; LMU Munich Munich Germany
| | - E. Hoster
- Department of Medicine III; University Hospital; LMU Munich Munich Germany
| |
Collapse
|
14
|
Dreyling M, Santoro A, Leppä S, Demeter J, Follows G, Lenz G, Kim W, Mollica L, Nagler A, Phipps Diong C, Provencio M, Magagnoli M, Munoz J, Hiemeyer F, Liu L, Miriyala A, Rodrigues L, Garcia-Vargas J, Childs B, Zinzani P. EFFICACY AND SAFETY IN HIGH-RISK RELAPSED OR REFRACTORY INDOLENT FOLLICULAR LYMPHOMA PATIENTS TREATED WITH COPANLISIB. Hematol Oncol 2019. [DOI: 10.1002/hon.57_2631] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Affiliation(s)
- M. Dreyling
- Department of Medicine III; University Hospital (LMU); Munich Germany
| | - A. Santoro
- Cancer Center; Humanitas Clinical and Research Center; Rozzano Italy
| | - S. Leppä
- Comprehensive Cancer Center; Helsinki University Hospital; Helsinki Finland
| | - J. Demeter
- First Department of Internal Medicine; Semmelweis University; Budapest Hungary
| | - G.A. Follows
- Haematology; Cambridge University Hospitals NHS Foundation Trust; Cambridge United Kingdom
| | - G. Lenz
- Translational Oncology; University Hospital Münster; Münster Germany
| | - W.S. Kim
- Hematology and Oncology; Sungkyunkwan University School of Medicine, Samsung Medical Center; Seoul Republic of Korea
| | - L. Mollica
- Clinical Research in Hematology and Clinical Oncology; Maisonneuve-Rosemont Hospital Research Centre; Montréal Quebec Canada
| | - A. Nagler
- Chaim Sheba Medical Center; Tel Aviv University; Tel HaShomer Israel
| | - C. Phipps Diong
- Department of Haematology; Singapore General Hospital; Bukit Merah Singapore
| | - M. Provencio
- Medical Oncology; Health Research Institute, Hospital Universitario Puerta de Hierro, Universidad Autónoma de Madrid; Madrid Spain
| | - M. Magagnoli
- Cancer Center; Humanitas Clinical and Research Center; Rozzano Italy
| | - J. Munoz
- Hematology and Oncology; Banner MD Anderson Cancer Center Clinic; Gilbert United States
| | - F. Hiemeyer
- Pharmaceutical Division; Bayer AG; Berlin Germany
| | - L. Liu
- Oncology; Bayer HealthCare Pharmaceuticals, Inc.; Whippany United States
| | - A. Miriyala
- Oncology; Bayer HealthCare Pharmaceuticals, Inc.; Whippany United States
| | | | - J. Garcia-Vargas
- Oncology; Bayer HealthCare Pharmaceuticals, Inc.; Whippany United States
| | - B.H. Childs
- Oncology; Bayer HealthCare Pharmaceuticals, Inc.; Whippany United States
| | - P.L. Zinzani
- Institute of Hematology “Seràgnoli”; University of Bologna; Bologna Italy
| |
Collapse
|
15
|
Panayiotidis P, Kellner A, Follows G, Mollica L, Nagler A, Özcan M, Santoro A, Hiemeyer F, Liu L, Garcia-Vargas J, Childs B, Zinzani P, Dreyling M. COPANLISIB TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MARGINAL ZONE LYMPHOMA. Hematol Oncol 2019. [DOI: 10.1002/hon.69_2631] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- P. Panayiotidis
- School of Medicine; National and Kapodistrian University of Athens; Athens Greece
| | - A. Kellner
- Hematology; Kaposi Mór Teaching Hospital; Kaposvár Hungary
| | - G.A. Follows
- Haematology; Cambridge University Hospitals NHS Foundation Trust; Cambridge United Kingdom
| | - L. Mollica
- Clinical Research in Hematology and Clinical Oncology; Maisonneuve-Rosemont Hospital Research Centre; Montréal Quebec Canada
| | - A. Nagler
- Chaim Sheba Medical Center; Tel Aviv University; Tel HaShomer Israel
| | - M. Özcan
- Hematology; Ankara University; Ankara Turkey
| | - A. Santoro
- Cancer Center; Humanitas Clinical and Research Center; Rozzano Italy
| | - F. Hiemeyer
- Pharmaceutical Division; Bayer AG; Berlin Germany
| | - L. Liu
- Oncology; Bayer HealthCare Pharmaceuticals, Inc.; Whippany United States
| | - J. Garcia-Vargas
- Oncology; Bayer HealthCare Pharmaceuticals, Inc.; Whippany United States
| | - B.H. Childs
- Oncology; Bayer HealthCare Pharmaceuticals, Inc.; Whippany United States
| | - P.L. Zinzani
- Institute of Hematology "Seràgnoli"; University of Bologna; Bologna Italy
| | - M. Dreyling
- Department of Medicine III; University Hospital (LMU); Munich Germany
| |
Collapse
|
16
|
Awan F, Chan R, Gu L, Xing G, Bhargava P, Ruzicka B, Dreyling M, Zinzani P, Gopal A. TREATMENT EMERGENT ADVERSE EVENTS VARY WITH DIFFERENT PI3K INHIBITORS. Hematol Oncol 2019. [DOI: 10.1002/hon.208_2631] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- F.T. Awan
- Harold C. Simmons Comprehensive Cancer Center; University of Texas Southwestern Medical Center; Dallas United States
| | - R.J. Chan
- Medical Affairs; Gilead Sciences, Inc.; Foster City United States
| | - L. Gu
- Biostatistics; Gilead Sciences, Inc.; Seattle United States
| | - G. Xing
- Biostatistics; Gilead Sciences, Inc.; Seattle United States
| | - P. Bhargava
- Medical Affairs; Gilead Sciences, Inc.; Foster City United States
| | - B. Ruzicka
- Medical Affairs; Gilead Sciences, Inc.; Foster City United States
| | - M. Dreyling
- Department of Medicine III; University Hospital of the Ludwig Maximilians University Munich; München Germany
| | - P. Zinzani
- Institute of Hematology “L. e A. Seràgnoli”; University of Bologna; Bologna Italy
| | - A.K. Gopal
- Fred Hutchinson Cancer Research Center; Seattle Cancer Care Alliance, University of Washington; Seattle United States
| |
Collapse
|
17
|
Dickinson M, Popplewell L, Kolstad A, Ho P, Teshima T, Dreyling M, Schuster S, Thieblemont C, Ghosh M, Riedell P, Yateman N, Lehnhoff K, Lawniczek T, Pacaud L, Fowler N. ELARA: A PHASE 2 TRIAL INVESTIGATING THE EFFICACY AND SAFETY OF TISAGENLECLEUCEL IN ADULT PATIENTS WITH REFRACTORY/RELAPSED FOLLICULAR LYMPHOMA. Hematol Oncol 2019. [DOI: 10.1002/hon.6_2632] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- M. Dickinson
- Integrated Haematology Service; Peter MacCallum Cancer Centre; Melbourne Australia
| | - L. Popplewell
- Department of Hematology & Hematopoietic Cell Transplantation; City of Hope National Medical Center; Duarte United States
| | - A. Kolstad
- Department of Oncology; Oslo University Hospital; Oslo Norway
| | - P.J. Ho
- Institute of Haematology; Royal Prince Alfred Hospital; Camperdown Australia
| | - T. Teshima
- Department of Hematology; Hokkaido University Hospital; Sapporo Japan
| | - M. Dreyling
- Department of Medicine; University Hospital Grosshadern; München Germany
| | - S. Schuster
- Division of Hematology Oncology; University of Pennsylvania; Philadelphia United States
| | - C. Thieblemont
- Hemato-Oncology Department; Hospital Saint-Louis; Paris France
| | - M. Ghosh
- Michigan Medicine Bone Marrow Transplant and Leukemia; University of Michigan; Ann Arbor United States
| | - P. Riedell
- Biomedical Sciences; University of Chicago; Chicago United States
| | - N. Yateman
- External; Novartis Pharma AG; Basel Switzerland
| | - K. Lehnhoff
- Global Development Operations; Novartis Pharma AG; Basel Switzerland
| | - T. Lawniczek
- CAR-T Cell Therapy; Novartis Pharma AG; Basel Switzerland
| | - L. Pacaud
- Novartis Oncology; Novartis Pharmaceuticals Corporation; East Hanover United States
| | - N. Fowler
- Lymphoma and Meyloma; MD Anderson Cancer Center; Houston United States
| |
Collapse
|
18
|
Wang M, Belada D, Cheah C, Chu M, Dreyling M, Flinn I, Fogliatto L, Goy A, Inwards D, Jurczak W, Mayer J, Re F, Robak T, Spurgeon S, Yoon S, Zinzani P, Yin M, Chen T, Kahl B. A PHASE 3 STUDY OF ACALABRUTINIB PLUS BENDAMUSTINE AND RITUXIMAB IN ELDERLY (AGED ≥65 Years) TREATMENT-NAIVE PATIENTS WITH MANTLE CELL LYMPHOMA. Hematol Oncol 2019. [DOI: 10.1002/hon.2632] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- M. Wang
- Department of Lymphoma/Myeloma; The University of Texas MD Anderson Cancer Center; Houston United States
| | - D. Belada
- Charles University Hospital and Faculty of Medicine; Fourth Department of Internal Medicine-Hematology; Hradec Králové Czech Republic
| | - C. Cheah
- Comprehensive Cancer Centre; Sir Charles Gairdner Hospital; Nedlands WA Australia
| | - M.P. Chu
- Clinician Scientist; Cross Cancer Institute; Edmonton Canada
| | - M. Dreyling
- Medizinische Klinik und Poliklinik III; Klinikum der Universität München, LMU München; München Germany
| | - I. Flinn
- Lymphoma Research; Sarah Cannon; Nashville United States
| | - L. Fogliatto
- Hematology; Irmandade da Santa Case de Misericórdia; Porto Alegre Brazil
| | - A. Goy
- Lymphoma Division; John Theurer Cancer Center, Hackensack University Medical Center; Hackensack United States
| | - D. Inwards
- Hematology; Mayo Clinic; Rochester United States
| | - W. Jurczak
- Department of Hematology; Jagiellonian University; Krakow Poland
| | - J. Mayer
- Hematology; Fakultní nemocnice Brno; Brno Czech Republic
| | - F. Re
- Hematology; Azienda Ospedaliero-Universitaria di Parma; Parma Italy
| | - T. Robak
- Hematology; Medical University of Lodz, Copernicus Memorial Hospital; Lodz Poland
| | - S. Spurgeon
- Hematology and Medical Oncology; OHSU Knight Cancer Institute; Portland United States
| | - S.S. Yoon
- Hemato Oncology; Seoul National University Hospital; Seoul Republic of Korea
| | - P.L. Zinzani
- Hematology; Institute of Hematology Seràgnoli, University of Bologna; Bologna Italy
| | - M. Yin
- Bio statistics; Acerta Pharma; South San Francisco United States
| | - T. Chen
- Clinical Development; Acerta Pharma; South San Francisco United States
| | | | | |
Collapse
|
19
|
Zinzani P, Santoro A, Leppä S, Demeter J, Follows G, Lenz G, Kim W, Mollica L, Nagler A, Phipps Diong C, Provencio M, Magagnoli M, Munoz J, Miriyala A, Liu L, Zhang M, Garcia-Vargas J, Childs B, Dreyling M. SAFETY ANALYSIS OF PATIENTS WITH A MEDICAL HISTORY OF RESPIRATORY DISORDERS TREATED WITH COPANLISIB FROM THE CHRONOS-1 STUDY IN RELAPSED OR REFRACTORY INDOLENT B-CELL LYMPHOMA. Hematol Oncol 2019. [DOI: 10.1002/hon.58_2631] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- P.L. Zinzani
- Institute of Hematology “Seràgnoli”; University of Bologna; Bologna Italy
| | - A. Santoro
- Cancer Center; Humanitas Clinical and Research Center; Rozzano Italy
| | - S. Leppä
- Comprehensive Cancer Center; Helsinki University Hospital; Helsinki Finland
| | - J. Demeter
- First Department of Internal Medicine; Semmelweis University; Budapest Hungary
| | - G.A. Follows
- Haematology; Cambridge University Hospitals NHS Foundation Trust; Cambridge United Kingdom
| | - G. Lenz
- Translational Oncology; University Hospital Münster; Münster Germany
| | - W.S. Kim
- Samsung Medical Center; Sungkyunkwan University School of Medicine; Seoul Republic of Korea
| | - L. Mollica
- Clinical Research in Hematology and Clinical Oncology; Maisonneuve-Rosemont Hospital Research Centre; Montréal, Quebec Canada
| | - A. Nagler
- Chaim Sheba Medical Center; Tel Aviv University; Tel HaShomer Israel
| | - C. Phipps Diong
- Department of Haematology; Singapore General Hospital; Bukit Merah Singapore
| | - M. Provencio
- Health Research Institute; Hospital Universitario Puerta de Hierro, Universidad Autónoma de Madrid; Madrid Spain
| | - M. Magagnoli
- Cancer Center; Humanitas Clinical and Research Center; Rozzano Italy
| | - J. Munoz
- Hematology and Oncology; Banner MD Anderson Cancer Center Clinic; Gilbert United States
| | - A. Miriyala
- Oncology; Bayer HealthCare Pharmaceuticals, Inc.; Whippany United States
| | - L. Liu
- Oncology; Bayer HealthCare Pharmaceuticals, Inc.; Whippany United States
| | - M. Zhang
- Oncology; Bayer HealthCare Pharmaceuticals, Inc.; Whippany United States
| | - J. Garcia-Vargas
- Oncology; Bayer HealthCare Pharmaceuticals, Inc.; Whippany United States
| | - B.H. Childs
- Oncology; Bayer HealthCare Pharmaceuticals, Inc.; Whippany United States
| | - M. Dreyling
- Department of Medicine III; University Hospital (LMU); Munich Germany
| |
Collapse
|
20
|
Frontzek F, Ziepert M, Nickelsen M, Altmann B, Glaß B, Hänel M, Trümper L, Held G, Bentz M, Borchmann P, Dreyling M, Viardot A, Metzner B, Kroschinsky F, Staiger A, Ott G, Rosenwald A, Löffler M, Lenz G, Schmitz N. INTENSIVE IMMUNOCHEMOTHERAPY (R-CHOEP) VS HIGH-DOSE IMMUNOCHEMOTHERAPY (R-MegaCHOEP) IN YOUNG PATIENTS WITH AGGRESSIVE B-CELL LYMPHOMA: A 10-YEAR LONG-TERM FOLLOW-UP. Hematol Oncol 2019. [DOI: 10.1002/hon.104_2631] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- F. Frontzek
- Department of Hematology; Oncology and Pneumology, University Hospital Münster; Münster Germany
| | - M. Ziepert
- Institute for Informatics; Statistics and Epidemiology, University Leipzig; Leipzig Germany
| | - M. Nickelsen
- Oncology; Oncology Lerchenfeld, Hamburg; Germany
| | - B. Altmann
- Institute for Informatics; Statistics and Epidemiology, University Leipzig; Leipzig Germany
| | - B. Glaß
- Hematology and Stem Cell Transplantation; Helios-Klinikum Berlin-Buch; Berlin Germany
| | - M. Hänel
- Department of Internal Medicine III; Municipal Hospital Chemnitz; Chemnitz Germany
| | - L. Trümper
- Hematology and Oncology; University Göttingen; Göttingen Germany
| | - G. Held
- Departement of Internal Medicine I; Westpfalz-Klinikum GmbH; Kaiserlautern Germany
| | - M. Bentz
- Department of Internal Medicine III; Municipal Hospital Karlsruhe; Karlsruhe Germany
| | - P. Borchmann
- Department of Internal Medicine I; University Hospital Cologne; Cologne Germany
| | - M. Dreyling
- Department of Internal Medicine III; Ludwig-Maximilians University of München; München Germany
| | - A. Viardot
- Department of Internal Medicine III; University Hospital Ulm; Ulm Germany
| | - B. Metzner
- Oncology and Hematology; Hospital Oldenburg; Oldenburg Germany
| | - F. Kroschinsky
- Department Internal Medicine I; University Hospital Carl Gustav Carus; Dresden Germany
| | - A.M. Staiger
- Department of Clinical Pathology; Robert-Bosch Hospital; Stuttgart Germany
| | - G. Ott
- Department of Clinical Pathology; Robert-Bosch Hospital; Stuttgart Germany
| | - A. Rosenwald
- Institute of Pathology; University Würzburg; Würzburg Germany
| | - M. Löffler
- Institute for Informatics; Statistics and Epidemiology, University Leipzig; Leipzig Germany
| | - G. Lenz
- Department of Hematology; Oncology and Pneumology, University Hospital Münster; Münster Germany
| | - N. Schmitz
- Department of Hematology; Oncology and Pneumology, University Hospital Münster; Münster Germany
| |
Collapse
|
21
|
Rule S, Barreto W, Briones J, Carella A, Casasnovas O, Pocock C, Wendtner C, Zaja F, Robson S, Tschopp R, Dreyling M. EFFICACY AND SAFETY OF PROLONGED MAINTENANCE WITH SUBCUTANEOUS RITUXIMAB IN PATIENTS WITH RELAPSED OR REFRACTORY INDOLENT NHL: RESULTS OF THE PHASE III MABCUTE STUDY. Hematol Oncol 2019. [DOI: 10.1002/hon.43_2630] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- S. Rule
- Department of Haematology; Derriford Hospital and Plymouth University Medical School; Plymouth United Kingdom
| | - W.G. Barreto
- Hematology and Hemotherapy; Hemocentro Ribeirão Preto, University of São Paulo; São Paulo Brazil
| | - J. Briones
- Department of Hematology; Hospital de la Santa Creu i Sant Pau; Barcelona Spain
| | - A.M. Carella
- Division of Hematology and Stem Cell Transplantation Unit; L'Istituto di Ricovero e Cura a Carattere Scientifico Azienda Ospedaliera Universitaria "San Martino" - Istituto Nazionale per la Ricerca sul Cancro; Genova Italy
| | - O. Casasnovas
- Service d'Hématologie Clinique; Centre Hospitalier Universitaire François Mitterand; Dijon France
| | - C. Pocock
- Department of Haematology; Kent & Canterbury Hospital; Canterbury United Kingdom
| | - C.M. Wendtner
- Department I of Internal Medicine; Klinikum Schwabing; Munich Germany
| | - F. Zaja
- SC Ematologia; Azienda Sanitaria Universitaria Integrata di Trieste; Trieste Italy
| | - S. Robson
- Product Development Medical Affairs; Biometrics, F. Hoffmann-La Roche Ltd; Basel Switzerland
| | - R.R. Tschopp
- Product Development Medical Affairs; Oncology, F. Hoffmann-La Roche Ltd; Basel Switzerland
| | - M. Dreyling
- Department of Medicine III; Klinikum der Universität München (LMU); Munich Germany
| |
Collapse
|
22
|
Rule S, Jurczak W, Jerkeman M, Rusconi C, Trneny M, Offner F, Caballero D, Joao C, Witzens-Harig M, Hess G, Bence-Bruckler I, Cho SG, Thieblemont C, Zhou W, Henninger T, Goldberg J, Vermeulen J, Dreyling M. Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study. Leukemia 2018; 32:1799-1803. [PMID: 29572505 PMCID: PMC6087720 DOI: 10.1038/s41375-018-0023-2] [Citation(s) in RCA: 63] [Impact Index Per Article: 10.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/08/2017] [Revised: 11/21/2017] [Accepted: 12/22/2017] [Indexed: 11/23/2022]
Affiliation(s)
- S Rule
- Plymouth University Medical School, Plymouth, UK.
| | - W Jurczak
- Department of Hematology, Jagiellonian University, Krakow, Poland
| | - M Jerkeman
- Skånes University Hospital, Lund University, Lund, Sweden
| | - C Rusconi
- Hematology Division, Hematology and Oncology Department, Niguarda Cancer Center, Niguarda Hospital, Milan, Italy
| | - M Trneny
- Ist Dept Medicine, Charles University General Hospital, Prague, Czech Republic
| | - F Offner
- Departement Oncologie, UZ Gent, Ghent, Belgium
| | - D Caballero
- Instituto Biosanitario de Salamanca, Hospital Clinico Universitario Salamanca, Salamanca, Spain
| | - C Joao
- Institutto Português de Oncologia de Lisboa, Portugal and Champalimaud Centre for the Unknown, Hematology, Lisbon, Portugal
| | - M Witzens-Harig
- Klinikum der Ruprechts-Karls-Universität Heidelberg, Med. Klinik u. Poliklinik V, Heidelberg, Germany
| | - G Hess
- Department of Hematology, Oncology and Pneumology, University Medical School of the Johannes Gutenberg University, Mainz, Germany
| | | | - S-G Cho
- Seoul St. Mary's Hospital, Seocho-gu, Seoul, South Korea
| | - C Thieblemont
- APHP, Saint-Louis Hospital, Hemato-oncology, Diderot University, Paris, France
| | - W Zhou
- Janssen Research & Development, Raritan, NJ, USA
| | - T Henninger
- Janssen Research & Development, Raritan, NJ, USA
| | - J Goldberg
- Janssen Research & Development, Raritan, NJ, USA
| | - J Vermeulen
- Janssen Research & Development, Leiden, The Netherlands
| | - M Dreyling
- Department of Medicine III, Klinikum der Universität München, LMU, Munich, Germany
| |
Collapse
|
23
|
Dreyling M, Ghielmini M, Rule S, Salles G, Vitolo U, Ladetto M. Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2018; 27:v83-v90. [PMID: 27664263 DOI: 10.1093/annonc/mdw400] [Citation(s) in RCA: 150] [Impact Index Per Article: 25.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- M Dreyling
- Department of Medicine III, University of Munich, Germany
| | - M Ghielmini
- Oncology Institute of Southern Switzerland, Ospedale San Giovanni, Bellinzona, Switzerland
| | - S Rule
- Haematology, Peninsula School of Medicine, Plymouth, UK
| | - G Salles
- Hospices Civils de Lyon, Centre Hospitalier Lyon-Sud, Service d'Hématologie & Université Claude Bernard Lyon-1, Pierre-Benite, France
| | - U Vitolo
- Haematology, University-Hospital Città della Salute e della Scienza, Torino
| | - M Ladetto
- Divisione di Ematologia, Azienda Ospedaliera Santi Antonio e Biagio e Cesare Arrigo, Alessandria, Italy
| | | |
Collapse
|
24
|
Dreyling M, Morschhauser F, Bouabdallah K, Bron D, Cunningham D, Assouline SE, Verhoef G, Linton K, Thieblemont C, Vitolo U, Hiemeyer F, Giurescu M, Garcia-Vargas J, Gorbatchevsky I, Liu L, Koechert K, Peña C, Neves M, Childs BH, Zinzani PL. Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma. Ann Oncol 2018. [PMID: 28633365 PMCID: PMC5834070 DOI: 10.1093/annonc/mdx289] [Citation(s) in RCA: 183] [Impact Index Per Article: 30.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022] Open
Abstract
Background Copanlisib is a pan-class I phosphatidylinositol 3-kinase inhibitor with predominant activity against the α- and δ-isoforms. Patients and methods This phase II study evaluated the response rate of copanlisib administered intravenously on days 1, 8, and 15 of a 28-day cycle, in patients with indolent or aggressive malignant lymphoma. Archival tumor tissues were used for immunohistochemistry, gene-expression profiling, and mutation analysis. Results Thirty-three patients with indolent lymphoma and 51 with aggressive lymphoma received copanlisib. Follicular lymphoma (48.5%) and peripheral T-cell lymphoma (33.3%) were the most common histologic subtypes. Most patients (78.6%) had received prior rituximab and 54.8% were rituximab-refractory. Median duration of treatment was 23 and 8 weeks in the indolent and aggressive cohorts, respectively (overall range 2-138). Eighty patients were evaluated for efficacy. The objective response rate was 43.7% (14/32) in the indolent cohort and 27.1% (13/48) in the aggressive cohort; median progression-free survival was 294 days (range 0-874) and 70 days (range 0-897), respectively; median duration of response was 390 days (range 0-825) and 166 days (range 0-786), respectively. Common adverse events included hyperglycemia (57.1%; grade ≥3, 23.8%), hypertension (54.8%; grade ≥3, 40.5%), and diarrhea (40.5%; grade ≥3, 4.8%), all generally manageable. Neutropenia occurred in 28.6% of patients (grade 4, 11.9%). Molecular analyses showed enhanced antitumor activity in tumors with upregulated phosphatidylinositol 3-kinase pathway gene expression. Conclusion Intravenous copanlisib demonstrated promising efficacy and manageable toxicity in heavily pretreated patients with various subtypes of indolent and aggressive malignant lymphoma. Subtype-specific studies of copanlisib in patients with follicular, peripheral T-cell, and mantle cell lymphomas are ongoing. This trial is registered with ClinicalTrials.gov number NCT01660451 (Part A).
Collapse
Affiliation(s)
- M Dreyling
- Department of Medicine III, University Hospital, LMU Munich, Munich, Germany
| | - F Morschhauser
- Hematology Department, Hôpital Claude Huriez, Unité GRITA, Lille University, Lille
| | - K Bouabdallah
- Department of Hematology and Cellular Therapy, University Hospital of Bordeaux, Pessac, France
| | - D Bron
- Department of Clinical and Experimental Hematology, Jules Bordet Institute (Free University of Brussels - ULB), Brussels, Belgium
| | - D Cunningham
- Department of Clinical and Experimental Haematology, The Royal Marsden Hospital, Sutton, UK
| | - S E Assouline
- Division of Hematology, Jewish General Hospital, Montreal, Canada
| | - G Verhoef
- Department of Haematology, University Hospital Leuven, Leuven, Belgium
| | - K Linton
- Department of Haemato-oncology, The Christie NHS Foundation Trust, Manchester, UK
| | - C Thieblemont
- Department of Hemato-oncology, APHP-Hôpital Saint-Louis, Paris.,Diderot University, Sorbonne Paris Cité, Paris.,EA3788, Descartes University, Paris, France
| | - U Vitolo
- Department of Oncology and Hematology, Città della Salute e della Scienza di Torino, Torino, Italy
| | | | | | | | | | - L Liu
- Bayer HealthCare Pharmaceuticals, Inc., Whippany, USA
| | | | - C Peña
- Bayer HealthCare Pharmaceuticals, Inc., Whippany, USA
| | | | - B H Childs
- Bayer HealthCare Pharmaceuticals, Inc., Whippany, USA
| | - P L Zinzani
- Department of Hematology and Oncology, Policlinico S. Orsola-Malpighi, Bologna, Italy
| |
Collapse
|
25
|
Ladetto M, Buske C, Hutchings M, Dreyling M, Gaidano G, Le Gouill S, Luminari S, Pott C, Zamò A, Zucca E. ESMO consensus conference on malignant lymphoma: general perspectives and recommendations for prognostic tools in mature B-cell lymphomas and chronic lymphocytic leukaemia. Ann Oncol 2018; 29:525. [PMID: 28368466 DOI: 10.1093/annonc/mdx061] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
26
|
Dreyling M, Ghielmini M, Rule S, Salles G, Vitolo U, Ladetto M. Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2017; 28:3109. [PMID: 28327933 DOI: 10.1093/annonc/mdx020] [Citation(s) in RCA: 25] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
27
|
Abstract
Pharmacological agents that inhibit enzymes of the B-cell receptor (BCR) pathway are of increasing importance in the treatment of B-cell malignancies. These include inhibitors of Bruton tyrosine kinase (BTK), phosphatidylinositol 3-kinase (PI3K), splenic tyrosine kinase and protein kinase Cβ. Two agents are already approved in the USA and Europe: ibrutinib, a BTK inhibitor, for the treatment of chronic lymphatic leukaemia (CLL), mantle cell lymphoma (MCL) and Waldenström's macroglobulinemia; and idelalisib, a PI3Kδ inhibitor, for the treatment of CLL and follicular lymphoma. In addition, the role of these drugs in diffuse large B-cell lymphoma and marginal zone lymphoma is under investigation, as single agents and in combination with chemotherapy. In CLL, both ibrutinib and idelalisib have an established role as first-line therapy in patients with del(17p), and in MCL, ibrutinib is a standard option for patients relapsing after chemoimmunotherapy. Unexpected toxicities have been encountered when combining these potent new agents with other drugs, including chemotherapy and lenalidomide, and based on this experience the risks and benefits of novel combinations must be evaluated carefully. In this review, we summarize the efficacy and safety results with these inhibitors and discuss novel combinations that are under study and the future role of BCR inhibitors in these disorders.
Collapse
Affiliation(s)
- M Jerkeman
- Department of Oncology, Lund University, Lund, Sweden
| | - M Hallek
- Department of Internal Medicine I, Cologne University Hospital, Cologne, Germany
| | - M Dreyling
- Department of Medicine III, University of Munich, Munich, Germany
| | - C Thieblemont
- Hemato-Oncology, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France
| | - E Kimby
- Hematology Center, Department of Medicine, Karolinska Institute, Stockholm, Sweden
| | - L Staudt
- Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
| |
Collapse
|
28
|
Dreyling M, Hess G, Krekeler G. Evaluation of safety, tolerability and efficacy of temsirolimus in patients (pts) with relapsed or refractory mantle cell lymphoma (rel/refr MCL) in routine clinical practice. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx373.029] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
29
|
Liu L, Köchert K, Seidel H, Garcia-Vargas J, Childs B, Follows G, Bouabdallah K, Dreyling M, Peña C. Tumor gene expression signatures of BCR/PI3K dependence in association with copanlisib monotherapy activity in heavily pretreated patients with indolent NHL and follicular lymphoma. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx373.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
30
|
Provencio Pulla M, Santoro A, Mollica L, Leppä S, Follows G, Lenz G, Kim W, Nagler A, Panayiotidis P, Demeter J, Özcan M, Kosinova M, Bouabdallah K, Morschhauser F, Ishida T, Huang L, Garcia-Vargas J, Childs B, Zinzani P, Dreyling M. Copanlisib treatment in patients with relapsed or refractory indolent B-cell lymphoma: Subgroup analyses from the CHRONOS-1 study. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx373.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
31
|
Affiliation(s)
- T. Seiler
- Department of Internal Medicine III, University Hospital Grosshadern, Ludwig Maximilians University (LMU), Munich, Germany
| | - M. Dreyling
- Department of Internal Medicine III, University Hospital Grosshadern, Ludwig Maximilians University (LMU), Munich, Germany
| |
Collapse
|
32
|
Younes A, Hilden P, Coiffier B, Hagenbeek A, Salles G, Wilson W, Seymour JF, Kelly K, Gribben J, Pfreunschuh M, Morschhauser F, Schoder H, Zelenetz AD, Rademaker J, Advani R, Valente N, Fortpied C, Witzig TE, Sehn LH, Engert A, Fisher RI, Zinzani PL, Federico M, Hutchings M, Bollard C, Trneny M, Elsayed YA, Tobinai K, Abramson JS, Fowler N, Goy A, Smith M, Ansell S, Kuruvilla J, Dreyling M, Thieblemont C, Little RF, Aurer I, Van Oers MHJ, Takeshita K, Gopal A, Rule S, de Vos S, Kloos I, Kaminski MS, Meignan M, Schwartz LH, Leonard JP, Schuster SJ, Seshan VE. International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017). Ann Oncol 2017; 28:1436-1447. [PMID: 28379322 PMCID: PMC5834038 DOI: 10.1093/annonc/mdx097] [Citation(s) in RCA: 200] [Impact Index Per Article: 28.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/24/2017] [Indexed: 12/20/2022] Open
Abstract
In recent years, the number of approved and investigational agents that can be safely administered for the treatment of lymphoma patients for a prolonged period of time has substantially increased. Many of these novel agents are evaluated in early-phase clinical trials in patients with a wide range of malignancies, including solid tumors and lymphoma. Furthermore, with the advances in genome sequencing, new "basket" clinical trial designs have emerged that select patients based on the presence of specific genetic alterations across different types of solid tumors and lymphoma. The standard response criteria currently in use for lymphoma are the Lugano Criteria which are based on [18F]2-fluoro-2-deoxy-D-glucose positron emission tomography or bidimensional tumor measurements on computerized tomography scans. These differ from the RECIST criteria used in solid tumors, which use unidimensional measurements. The RECIL group hypothesized that single-dimension measurement could be used to assess response to therapy in lymphoma patients, producing results similar to the standard criteria. We tested this hypothesis by analyzing 47 828 imaging measurements from 2983 individual adult and pediatric lymphoma patients enrolled on 10 multicenter clinical trials and developed new lymphoma response criteria (RECIL 2017). We demonstrate that assessment of tumor burden in lymphoma clinical trials can use the sum of longest diameters of a maximum of three target lesions. Furthermore, we introduced a new provisional category of a minor response. We also clarified response assessment in patients receiving novel immune therapy and targeted agents that generate unique imaging situations.
Collapse
Affiliation(s)
| | - P. Hilden
- Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, USA
| | - B. Coiffier
- Hematology, Université Lyon-1, Lyon-Sud Charles Mérieux, Lyon, France
| | - A. Hagenbeek
- Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
| | - G. Salles
- Hematology, Université Lyon-1, Lyon-Sud Charles Mérieux, Lyon, France
| | - W. Wilson
- Lymphoid Malignancies Branch, National Cancer Institute, Bethesda, USA
| | - J. F. Seymour
- Peter MacCallum Cancer Centre and University of Melbourne, Australia
| | - K. Kelly
- Pediatrics Department, Roswell-Park Cancer Institute, Buffalo, USA
| | - J. Gribben
- Department of Haemato-Oncology, Barts Cancer Institute, London, UK
| | - M. Pfreunschuh
- Department of Internal Medicine, Universität des Saarlandes, Homburg, Germany
| | - F. Morschhauser
- Department of Hematology, Université de Lille 2, Lille, France
| | - H. Schoder
- Department of Radiology, Memorial Sloan-Kettering Cancer Center, New York
| | | | - J. Rademaker
- Department of Radiology, Memorial Sloan-Kettering Cancer Center, New York
| | - R. Advani
- Department of Oncology, Stanford University, Stanford
| | | | | | | | - L. H. Sehn
- British Columbia Cancer Agency, Vancouver, Canada
| | - A. Engert
- Department of Internal Medicine, University Hospital of Cologne, Cologne, Germany
| | | | - P.-L. Zinzani
- Department of Hematology, University of Bologna, Bologna
| | - M. Federico
- Department of Diagnostic Medicine, University of Modena, Modena, Italy
| | - M. Hutchings
- Department of Hematology, University of Copenhagen, Denmark
| | - C. Bollard
- Children’s National Health System, Washington, USA
| | - M. Trneny
- Lymphoma and Stem Cell Transplantation Program, Charles University, Prague, Czech Republic
| | | | - K. Tobinai
- Department of Hematology, National Cancer Center Hospital, Tokyo, Japan
| | - J. S. Abramson
- Massachusetts General Hospital, Center for Lymphoma, Boston
| | - N. Fowler
- U.T. M.D.Anderson Cancer Center, Houston
| | - A. Goy
- John Theurer Cancer Center, Hackensack University Medical Center, Hackensack
| | - M. Smith
- Cleveland Clinic, Cleveland, USA
| | | | - J. Kuruvilla
- Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Canada
| | - M. Dreyling
- Medicine Clinic III, Ludwig Maximilian University, Munich, Germany
| | | | - R. F. Little
- Divisions of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, USA
| | - I. Aurer
- Department of Hematology, University Hospital Centre Zagreb, Zagreb, Croatia
| | | | | | - A. Gopal
- Fred Hutchinson Cancer Research Center, Seattle, USA
| | - S. Rule
- Haematology Department, Plymouth University, UK
| | | | - I. Kloos
- Servier, Neuilly sur Seine, France
| | - M. S. Kaminski
- University of Michigan Comprehensive Cancer Center, Ann Arbor, USA
| | - M. Meignan
- Nuclear Medicine, Hôpitaux Universitaires Henri Mondor, Créteil, France
| | - L. H. Schwartz
- Columbia University College of Physicians and Surgeons and New York Presbyterian Hospital, New York
| | - J. P. Leonard
- Weill Cornell Medicine and and New York Presbyterian Hospital, New York
| | - S. J. Schuster
- University of Pennsylvania School of Medicine, Philadelphia, USA
| | - V. E. Seshan
- Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, USA
| |
Collapse
|
33
|
Dreyling M, Campo E, Hermine O, Jerkeman M, Le Gouill S, Rule S, Shpilberg O, Walewski J, Ladetto M. Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2017; 28:iv62-iv71. [PMID: 28881919 DOI: 10.1093/annonc/mdx223] [Citation(s) in RCA: 176] [Impact Index Per Article: 25.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open
Affiliation(s)
- M Dreyling
- Department of Medicine III, University Hospital - LMU Munich, Munich, Germany
| | - E Campo
- Hematopathology Section, Hospital Clinic of Barcelona, University of Barcelona, Barcelona, Spain
| | - O Hermine
- Department of Hematology, Imagine Institute and Descartes University, INSERM U1163 and CNRS ERL 8564, Necker Hospital, Paris, France
| | - M Jerkeman
- Department of Hematology, University Lund, Lund, Sweden
| | - S Le Gouill
- CHU de Nantes, Service d'Hématologie Clinique, Université de Nantes, Nantes, France
| | - S Rule
- Peninsula School of Medicine and Dentistry, University of Plymouth, Plymouth, UK
| | - O Shpilberg
- Institute of Hematology, Assuta Medical Center, Tel-Aviv, Israel
| | - J Walewski
- Department of Lymphoid Malignancy, Maria Sklodowska-Curie Institute and Oncology Centre, Warsaw, Poland
| | - M Ladetto
- Divisione di Ematologia, Azienda Ospedaliera Santi Antonio e Biagio e Cesare Arrigo, Alessandria, Italy
| |
Collapse
|
34
|
Hoster E, Unterhalt M, Hänel M, Prange-Krex G, Forstpointner R, Florschütz A, Graeven U, Frickhofen N, Wulf G, Lengfelder E, Lerchenmüller C, Schlag R, Dierlamm J, Fischer Von Weikersthal L, Ahmed A, Harich H, Rosenwald A, Klapper W, Dreyling M, Hiddemann W, Herold M. RITUXIMAB MAINTENANCE VERSUS OBSERVATION AFTER IMMUNOCHEMOTHERAPY (R-CHOP, R-MCP, R-FCM) IN PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA: A RANDOMISED TRIAL OF GLSG AND OSHO. Hematol Oncol 2017. [DOI: 10.1002/hon.2437_12] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- E. Hoster
- Medizinische Klinik III; Klinikum der Ludwig-Maximilians-Universität München; Munich Germany
| | - M. Unterhalt
- Medizinische Klinik III; Klinikum der Ludwig-Maximilians-Universität München; Munich Germany
| | - M. Hänel
- Klinik für Innere Medizin III; Klinikum Chemnitz; Chemnitz Germany
| | - G. Prange-Krex
- Innere Medizin, Hämatologie, Onkologie, Gemeinschaftspraxis; Dresden Germany
| | - R. Forstpointner
- Medizinische Klinik III; Klinikum der Ludwig-Maximilians-Universität München; Munich Germany
| | - A. Florschütz
- Klinik für Innere Medizin; Städtisches Klinikum Dessau; Dessau Germany
| | - U. Graeven
- Klinik für Hämatologie, Onkologie und Gastroenterologie; Kliniken Maria Hilf; Mönchengladbach Germany
| | - N. Frickhofen
- Klinik Innere Medizin III; HELIOS Dr. Horst Schmidt Kliniken Wiesbaden; Wiesbaden Germany
| | - G. Wulf
- Hämatologie und Medizinische Onkologie; Universitätsmedizin Göttingen; Göttingen Germany
| | - E. Lengfelder
- III. Medizinische Klinik; Klinikum Mannheim; Mannheim Germany
| | | | - R. Schlag
- Innere Medizin, Hämatologie u. Internistische Onkologie; Gemeinschaftspraxis; Würzburg Germany
| | - J. Dierlamm
- II. Medizinischen Klinik und Poliklinik; Universitätsklinikum Eppendorf; Hamburg Germany
| | | | - A. Ahmed
- Medizinische Klinik III; Städtisches Klinikum Braunschweig; Braunschweig Germany
| | - H. Harich
- Onkologie Hof, Medizinisches Versorgungszentrum; Hof Germany
| | - A. Rosenwald
- Institut für Pathologie; Universität Würzburg; Würzburg Germany
| | - W. Klapper
- Sektion Hämatopathologie und Lymphknotenregister; Universitätsklinikum Schleswig-Holstein; Kiel Germany
| | - M. Dreyling
- Medizinische Klinik III; Klinikum der Ludwig-Maximilians-Universität München; Munich Germany
| | - W. Hiddemann
- Medizinische Klinik III; Klinikum der Ludwig-Maximilians-Universität München; Munich Germany
| | - M. Herold
- Onkologisches Zentrum; HELIOS Klinikum Erfurt; Erfurt Germany
| |
Collapse
|
35
|
Pfreundschuh M, Christofyllakis K, Altmann B, Ziepert M, Haenel M, Viardot A, Neubauer A, Held G, Truemper L, Dreyling M, Kanz L, Hallek M, Schmitz N, Heintges T, Kölbel C, Buecker A, Ruebe C, Hellwig D, Berdel C, Poeschel V, Murawski N. RADIOTHERAPY TO BULKY DISEASE PET-NEGATIVE AFTER IMMUNOCHEMOTHERAPY CAN BE SPARED IN ELDERLY DLBCL PATIENTS: RESULTS OF a PLANNED INTERIM ANALYSIS OF THE FIRST 187 PATIENTS WITH BULKY DISEASE TREATED IN THE OPTIMAL > 60 STUDY OF THE DSHNHL. Hematol Oncol 2017. [DOI: 10.1002/hon.2437_119] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- M. Pfreundschuh
- Hematology/Oncology; Saarland University Hospital; Homburg Germany
| | | | - B. Altmann
- IMISE; University of Leipzig; Leipzig Germany
| | - M. Ziepert
- IMISE; University of Leipzig; Leipzig Germany
| | - M. Haenel
- Internal Medicine III; Chemnitz Hospital; Chemnitz Germany
| | - A. Viardot
- Internal Medicine III; University Hospital Ulm; Ulm Germany
| | - A. Neubauer
- Hematology/Oncology; University Hospital Marburg; Marburg Germany
| | - G. Held
- Hematology/Oncology; Saarland University Hospital; Homburg Germany
| | - L. Truemper
- Department of Internal Medicine; University Hospital Goettingen; Goettingen Germany
| | - M. Dreyling
- Department for Internal Medicine 3; University Hospital Muenchen - Großhadern; Muenchen Germany
| | - L. Kanz
- Hematology/Oncology; University Hospital Tuebingen; Tuebingen Germany
| | - M. Hallek
- Internal Medicine I; University Hospital Koeln; Koeln Germany
| | - N. Schmitz
- Hematology; ASKLEPIOS Clinic Hamburg; Hamburg Germany
| | - T. Heintges
- Internal Medicine II; Lukaskrankenhaus Neuss; Neuss Germany
| | - C. Kölbel
- Internal Medicine I, Krankenhaus der Barmherzigen Brüder Trier; Trier Germany
| | - A. Buecker
- Department for Radiology; Saarland University Hospital; Homburg Germany
| | - C. Ruebe
- Department for Radiotherapy; Saarland University Hospital; Homburg Germany
| | - D. Hellwig
- Department for Nuclearmedicine; University Hospital Regensburg; Regensburg Germany
| | - C. Berdel
- Department for Radiotherapy; Saarland University Hospital; Homburg Germany
| | - V. Poeschel
- Hematology/Oncology; Saarland University Hospital; Homburg Germany
| | - N. Murawski
- Hematology/Oncology; Saarland University Hospital; Homburg Germany
| |
Collapse
|
36
|
Witzens-Harig M, Viardot A, Keller U, Buske C, Hönig E, Atta J, Larosee P, Marks R, Dreyling M, Hess G. SAFETY AND CLINICAL ACTIVITY OF TEMSIROLIMUS IN COMBINATION WITH RITUXIMAB AND DHAP IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA-REPORT OF THE PROSPECTIVE, MULTICENTER PHASE II STORM TRIAL. Hematol Oncol 2017. [DOI: 10.1002/hon.2438_52] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Affiliation(s)
- M. Witzens-Harig
- Hematology/Oncology; University of Heidelberg Hospital; Heidelberg Germany
| | - A. Viardot
- Hematology/Oncology; University of Ulm Hospital; Ulm Germany
| | - U. Keller
- III. Medical Department of Hematology and Medical Oncology; Technical University of Munich; Munich Germany
| | - C. Buske
- Hematology/Oncology; University of Ulm Hospital; Ulm Germany
| | - E. Hönig
- Interdisziplinäres Zentrum Klinische Studien (IZKS); Universitätsmedizin der Johannes Gutenberg-Universität Mainz; Mainz Germany
| | - J. Atta
- Hematology/Oncology; Tumortherapie Center; Offenbach Germany
| | - P. Larosee
- Klinik für Innere Medizin II: Onkologie, Hämatologie, Immunologie, Infektiologie und Palliativmedizin, Schwarzwald Baar Klinikum; Villingen-Schwenningen Germany
| | - R. Marks
- Hämatologie, Onkologie und Stammzelltransplantation, Klinik für Innere Medizin I; Freiburg Germany
| | - M. Dreyling
- Department of Internal Medicine III; Ludwig-Maximilians University of Munich; Munich Germany
| | - G. Hess
- III Medizinische Klinik; Universitätsmedizin Mainz; Mainz Germany
| |
Collapse
|
37
|
Rule S, Jurczak W, Jerkeman M, Santucci Silva R, Rusconi C, Trneny M, Offner F, Caballero D, Joao C, Witzens-Harig M, Hess G, Bence-Bruckler I, Cho S, Thieblemont C, Zhou W, Henninger T, Goldberg J, Vermeulen J, Dreyling M. IBRUTINIB VS TEMSIROLIMUS: THREE-YEAR FOLLOW-UP OF PATIENTS WITH PREVIOUSLY TREATED MANTLE CELL LYMPHOMA FROM THE PHASE 3, INTERNATIONAL, RANDOMIZED, OPEN-LABEL RAY STUDY. Hematol Oncol 2017. [DOI: 10.1002/hon.2437_133] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Affiliation(s)
- S. Rule
- Haematology; Derriford Hospital; Plymouth UK
| | - W. Jurczak
- Hematology; Jagiellonian University; Krakow Poland
| | - M. Jerkeman
- Oncology; Skånes University Hospital; Lund Sweden
| | - R. Santucci Silva
- Oncology; Instituto de Ensino e Pesquisa Sao Lucas; Sao Paulo Brazil
| | - C. Rusconi
- Hematology and Oncology; Niguarda Hospital; Milan Italy
| | - M. Trneny
- First Department Medicine; Charles University General Hospital; Prague Czech Republic
| | | | - D. Caballero
- Hematology; Hospital Clinico Universitario Salamanca; Salamanca Spain
| | - C. Joao
- Oncology; Institutto Português de Oncologia de Lisboa; Lisbon Portugal
| | | | - G. Hess
- Hematology, Oncology and Pneumology; University Medical School of the Johannes Gutenberg University; Mainz Germany
| | | | - S. Cho
- Hematology; Seoul St. Mary's Hospital; Seoul Republic of Korea
| | | | - W. Zhou
- Oncology; Janssen Research & Development; Raritan USA
| | - T. Henninger
- Oncology; Janssen Research & Development; Raritan USA
| | - J.D. Goldberg
- Oncology; Janssen Research & Development; Raritan USA
| | - J. Vermeulen
- Oncology; Janssen Research & Development; Beerse Belgium
| | - M. Dreyling
- Medicine III; Klinikum der Universität München, LMU; Munich Germany
| |
Collapse
|
38
|
Salles G, González Barca E, Jurczak W, Liberati A, Duell J, Nagy Z, Papajík T, Andre M, Kalakonda N, Dreyling M, Zinzani P, Ambarkhane S, Weirather J, Maddocks K. L-MIND: MOR208 COMBINED WITH LENALIDOMIDE (LEN) IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (R-R DLBCL) - A SINGLE-ARM PHASE II STUDY. Hematol Oncol 2017. [DOI: 10.1002/hon.2437_35] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Affiliation(s)
- G. Salles
- Service d'Hématologie, Hospices Civils de Lyon; Centre Hospitalier Lyon Sud; Pierre Bénite France
| | - E. González Barca
- Department of Hematology, Institut Catalá d'Oncología; Hospital Duran i Reynals, IDIBELL; Barcelona Spain
| | - W. Jurczak
- Department of Hematology; Jagiellonian University; Kraków Poland
| | - A.M. Liberati
- SC Oncoematologia; Azienda Ospedaliera Santa Maria; Terni Italy
| | - J. Duell
- Medizinische Klinik und Poliklinik II; University Hospital of Würzburg; Würzburg Germany
| | - Z. Nagy
- First Department of Internal Medicine; Semmelweis University; Budapest Hungary
| | - T. Papajík
- Department of Hemato-Oncology; Palacký University Olomouc and the University Hospital Olomouc; Olomouc Czech Republic
| | - M. Andre
- Department of Hematology, Université catholique de Louvain; CHU UCL Namur; Yvoir Belgium
| | - N. Kalakonda
- Department of Haematology; Royal Liverpool University Hospital; Liverpool UK
| | - M. Dreyling
- Medizinische Klinik und Poliklinik III; University Hospital of LMU; Munich Germany
| | - P.L. Zinzani
- Institute of Hematology “L. e A. Seràgnoli”; University of Bologna; Bologna Italy
| | | | - J. Weirather
- Clinical Development; MorphoSys AG; Planegg Germany
| | - K. Maddocks
- Department of Internal Medicine, Division of Hematology; The Ohio State University Comprehensive Cancer Center; Columbus Ohio USA
| |
Collapse
|
39
|
Aukema S, Hoster E, Rosenwald A, Canoni D, Rymkiewicz G, Thorns C, Hartmann S, Kluin-Nelemans H, Hermine O, Dreyling M, Klapper W. P53 BUT NOT SOX11 IHC HAS PROGNOSTIC VALUE INDEPENDENT OF MIPI AND KI-67 IN PROSPECTIVE TRIALS OF THE EUROPEAN-MCL NETWORK. Hematol Oncol 2017. [DOI: 10.1002/hon.2437_129] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- S.M. Aukema
- Dept. of Pathology and Hematopathology Section and Lymph Node Registry; Christian Albrechts University of Kiel; Kiel Germany
| | - E. Hoster
- Department of Internal Medicine III; University Hospital Munich; Munich Germany
| | - A. Rosenwald
- Department of Pathology; University of Würzburg; Würzburg Germany
| | - D. Canoni
- Department of Pathology, Hôpital Necker; Assistance Publique Hôpitaux de Paris; Paris France
| | - G. Rymkiewicz
- Department of Pathology; The Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology; Warsaw Poland
| | - C. Thorns
- Department of Pathology; University Hospital Schleswig-Holstein, Lübeck; Lübeck Germany
| | - S. Hartmann
- Department of Pathology; University Hospital of Frankfurt; Frankfurt am Main Germany
| | - H.C. Kluin-Nelemans
- Department of Hematology; University Medical Center Groningen; Groningen Netherlands
| | - O. Hermine
- Department of Hematology, Hôpital Necker, Assistance Publique Hôpitaux de Paris; University Paris Descartes; Paris France
| | - M. Dreyling
- Department of Internal Medicine III; University Hospital Munich; Munich Germany
| | - W. Klapper
- Dept. of Pathology and Hematopathology Section and Lymph Node Registry; Christian Albrechts University of Kiel; Kiel Germany
| |
Collapse
|
40
|
Ribrag V, Feugier P, Doorduijn J, Delfau-Larue M, Hermine O, Kluin-Nelemans H, Dasilva M, Lopez-Hernandez A, Walewski J, Szymczyk M, Pott C, Homburg C, Van der Velden V, Gameiro P, Garcia-Sanz R, Ladetto M, van Krieken H, Cabeçadas J, Rymkiewicz G, Klapper W, Hoster E, Le Gouill S, Dreyling M. MCL-R2 ELDERLY: A PHASE III STUDY OF THE EUROPEAN MCL NETWORK
ASSESSING EFFICACY OF ALTERNATING IMMUNOCHEMOTHERAPY (R-CHOP / R-HAD) AND a RITUXIMAB-LENALIDOMIDE MAINTENANCE. Hematol Oncol 2017. [DOI: 10.1002/hon.2440_3] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- V. Ribrag
- Hematology; Gustave Roussy Cancer Campus; Villejuif France
| | - P. Feugier
- Hematology; Hôpitaux De Brabois; Vandoeuvre-Les-Nancy France
| | - J. Doorduijn
- Hematology; Department of Hematology, Erasmus MC; Rotterdam Netherlands
| | - M. Delfau-Larue
- Hématologie et Immunologie Biologiques; GH Henri Mondor; Creteil France
| | - O. Hermine
- Hematology; Groupe Hospitalier : Hôpital Universitaire Necker-Enfants Malades; Paris France
| | - H. Kluin-Nelemans
- Department of Hematology; University Medical Center Groningen, University of Groningen; Groningen Netherlands
| | - M. Dasilva
- Serviço De Hematologia; Instituto Português De Oncologia De Lisboa; Lisbon Portugal
| | | | - J. Walewski
- Lymphoid Malignancy; Maria Sklodowska-Curie Institute - Oncology Center; Warszawa Poland
| | - M. Szymczyk
- Lymphoid Malignancy; Maria Sklodowska-Curie Institute - Oncology Center; Warszawa Poland
| | - C. Pott
- Klinisch-Experimentelle Hämatologie; Universitätsklinikum Schleswig-Holstein; Kiel Germany
| | - C. Homburg
- Laboratoriumhoofd Immunocytologie; Sanquin Diagnostiek; Amsterdam Netherlands
| | - V. Van der Velden
- Hematology; Department of Hematology, Erasmus MC; Rotterdam Netherlands
| | - P. Gameiro
- Biologia Molecular Laboratório De Hemato-Oncologia; Instituto Português De Oncologia De Lisboa; Lisbon Portugal
| | | | - M. Ladetto
- Hematology; Azienda Ospedaliera Nazionale SS.Antonio e Biagio e C. Arrigo; Alessandria Italy
| | - H. van Krieken
- Pathology; Radboud University Medical Center; Nijmegen Netherlands
| | - J. Cabeçadas
- Serviço De Anatomia Patológica; Instituto Português De Oncologia De Lisboa; Lisbon Portugal
| | - G. Rymkiewicz
- Lymphoid Malignancy; Maria Sklodowska-Curie Institute - Oncology Center; Warszawa Poland
| | - W. Klapper
- Institut Für Pathologie, Sektion Hämatopathologie und Lymphknotenregister; Universitätsklinikum Schleswig-Holstein, Campus Kiel; Kiel Germany
| | - E. Hoster
- Department of Medicine III; University Hospital of Munich; Munich Germany
| | - S. Le Gouill
- Service d'Hématologie; CHU de Nantes; Nantes France
| | - M. Dreyling
- Department of Medicine III; University Hospital of Munich; Munich Germany
| |
Collapse
|
41
|
Alig S, Jurinovic V, Dreyling M, Pastore A, Kridel R, Gascoyne R, Hiddemann W, Unterhalt M, Hoster E, Weigert O. HIGHER MUTATIONAL BURDEN BUT DOES NOT IMPACT TREATMENT EFFICACY IN FOLLICULAR LYMPHOMA. Hematol Oncol 2017. [DOI: 10.1002/hon.2437_86] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Affiliation(s)
- S. Alig
- Medical Department III; Ludwig-Maximilians-University; Munich Germany
| | - V. Jurinovic
- Medical Department III & Institute for Medical Informatics, Biometry and Epidemiology; Ludwig-Maximilians-University; Munich Germany
| | - M. Dreyling
- Medical Department III; Ludwig-Maximilians-University; Munich Germany
| | - A. Pastore
- Human Oncology and Pathogenesis Program; Memorial Sloan Kettering Cancer Center; New York USA
| | - R. Kridel
- Division of Medical Oncology and Hematology; Princess Margaret Cancer Centre - University Health Network; Toronto Canada
| | - R. Gascoyne
- Centre for Lymphoid Cancer & Department of Pathology and Laboratory Medicine, BC Cancer Agency; Vancouver Canada
| | - W. Hiddemann
- Medical Department III; Ludwig-Maximilians-University; Munich Germany
| | - M. Unterhalt
- Medical Department III; Ludwig-Maximilians-University; Munich Germany
| | - E. Hoster
- Medical Department III & Institute for Medical Informatics, Biometry and Epidemiology; Ludwig-Maximilians-University; Munich Germany
| | - O. Weigert
- Medical Department III; Ludwig-Maximilians-University; Munich Germany
| |
Collapse
|
42
|
Morello L, Rattotti S, Jerkeman M, van Meerten T, Krawczyk K, Moita F, Marino D, Ferrero S, Szymczyk M, Aurer I, El-Galaly T, Di Rocco A, Carli G, Defrancesco I, Giordano L, Carlo-Stella C, Dreyling M, Santoro A, Arcaini L. MANTLE CELL LYMPHOMA OF MUCOSA-ASSOCIATED LYMPHOID TISSUE: A RETROSPECTIVE MULTICENTER OBSERVATIONAL STUDY OF THE EUROPEAN MANTLE CELL LYMPHOMA NETWORK. Hematol Oncol 2017. [DOI: 10.1002/hon.2438_66] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- L. Morello
- Department of Oncology and Hematology; Humanitas Clinical and Research Center, Rozzano, Italy; Rozzano (MI) Italy
| | - S. Rattotti
- Department of Hematology and Oncology, Fondazione IRCCS Policlinico S. Matteo; University of Pavia, Italy; Pavia Italy
| | - M. Jerkeman
- Department of Oncology; Skane University Hospital; Lund Sweden
| | - T. van Meerten
- Department of Hematology; University Medical Center Groningen; Groningen The Netherlands
| | - K. Krawczyk
- Department of Hematology; Jagiellonian University; Krakow Poland
| | - F. Moita
- Instituto Português de Oncologia de Lisboa, Francisco Gentil; Lisbon Portugal
| | - D. Marino
- Oncology Unit 1; Veneto Institute of Oncology IOV-IRCCS; Padova Italy
| | - S. Ferrero
- Division of Hematology, Department of Molecular Biotechnologies and Health Sciences; University of Torino; Torino Italy
| | - M. Szymczyk
- Department of Lymphoid Malignancies, The Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology; Warsaw Poland
| | - I. Aurer
- Division of Hematology, Department of Internal Medicine; University Hospital Centre Zagreb; Zagreb Croatia
| | - T.C. El-Galaly
- Department of Hematology; Aalborg University Hospital; Aalborg Denmark
| | - A. Di Rocco
- Department of Cellular Biotechnologies and Hematology; Sapienza University; Rome Italy
| | - G. Carli
- Department of Cell Therapy and Haematology; San Bortolo Hospital; Vicenza Italy
| | - I. Defrancesco
- Department of Hematology and Oncology, Fondazione IRCCS Policlinico S. Matteo; University of Pavia, Italy; Pavia Italy
| | - L. Giordano
- Department of Oncology and Hematology; Humanitas Clinical and Research Center, Rozzano, Italy; Rozzano (MI) Italy
| | - C. Carlo-Stella
- Department of Oncology and Hematology; Humanitas Clinical and Research Center, Rozzano, Italy; Rozzano (MI) Italy
| | - M. Dreyling
- Department of Internal Medicine III; Ludwig-Maximilians University Hospital Munich; Munchen Germany
| | - A. Santoro
- Department of Oncology and Hematology; Humanitas Clinical and Research Center, Rozzano, Italy; Rozzano (MI) Italy
| | - L. Arcaini
- Department of Hematology and Oncology, Fondazione IRCCS Policlinico S. Matteo; University of Pavia, Italy; Pavia Italy
| |
Collapse
|
43
|
Dreyling M, Santoro A, Mollica L, Leppä S, Follows G, Lenz G, Kim W, Nagler A, Panayiotidis P, Demeter J, Özcan M, Kosinova M, Bouabdallah K, Morschhauser F, Stevens D, Trevarthen D, Giurescu M, Liu L, Koechert K, Peña C, Cupit L, Yin S, Hiemeyer F, Garcia-Vargas J, Childs B, Zinzani P. COPANLISIB IN PATIENTS WITH RELAPSED OR REFRACTORY INDOLENT B-CELL LYMPHOMA (CHRONOS-1). Hematol Oncol 2017. [DOI: 10.1002/hon.2437_107] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- M. Dreyling
- Medizinische Klinik und Poliklinik III; Klinikum der Universität München-Grosshadern; Munich Germany
| | - A. Santoro
- Department of Oncology and Hematology, Humanitas Cancer Center; Humanitas Clinical and Research Institute; Rozzano MI Italy
| | - L. Mollica
- Department of Hematology; Hôpital Maisonneuve-Rosemont-Montreal; Montreal Quebec Canada
| | - S. Leppä
- Department of Oncology; Helsinki University Central Hospital Cancer Center; Helsinki Finland
| | - G.A. Follows
- Department of Haematology; Cambridge University Hospitals NHS Foundation Trust Addenbrooke's Hospital; Cambridge UK
| | - G. Lenz
- Translational Oncology; University Hospital Münster; Münster Germany
| | - W. Kim
- Division of Hematology and Oncology, Department of Medicine; Sungkyunkwan University School of Medicine, Samsung Medical Center; Seoul Republic of Korea
| | - A. Nagler
- Hematology Division; Chaim Sheba Medical Center- Tel Aviv University; Tel-Hashomer Israel
| | - P. Panayiotidis
- Division of Hematology; Laikon University Hospital, National and Kapodistrian University of Athens; Athens Greece
| | - J. Demeter
- First Department of Internal Medicine, Division of Haematology; Semmelweis University; Budapest Hungary
| | - M. Özcan
- Department of Hematology; Ankara University School of Medicine; Ankara Turkey
| | - M. Kosinova
- Department of Hematology; Kemerovo Regional Clinical Hospital; Kemerovo Russian Federation
| | - K. Bouabdallah
- Service d'Hématologie et de Thérapie Cellulaire; University Hospital of Bordeaux; Pessac France
| | - F. Morschhauser
- Department of Hematology; CHRU - Hôpital Claude Huriez; Lille France
| | - D.A. Stevens
- Medical Oncology; Norton Cancer Institute; Louisville-KY USA
| | - D. Trevarthen
- Medical Oncology; Comprehensive Cancer Care and Research Institute of Colorado; Englewood-CO USA
| | - M. Giurescu
- Pharmaceutical Division, Bayer AG; Berlin Germany
| | - L. Liu
- Biomarkers; Bayer HealthCare Pharmaceuticals Inc; Whippany-NJ USA
| | - K. Koechert
- Pharmaceutical Division, Bayer AG; Berlin Germany
| | - C. Peña
- Biomarkers; Bayer HealthCare Pharmaceuticals Inc; Whippany-NJ USA
| | - L. Cupit
- Clinical Development; Bayer HealthCare Pharmaceuticals Inc; Whippany-NJ USA
| | - S. Yin
- Clinical Development; Bayer HealthCare Pharmaceuticals Inc; Whippany-NJ USA
| | - F. Hiemeyer
- Pharmaceutical Division, Bayer AG; Berlin Germany
| | - J. Garcia-Vargas
- Clinical Development; Bayer HealthCare Pharmaceuticals Inc; Whippany-NJ USA
| | - B.H. Childs
- Clinical Development; Bayer HealthCare Pharmaceuticals Inc; Whippany-NJ USA
| | - P. Zinzani
- Department of Hematology; Institute of Hematology "L. e A. Seràgnoli"- University of Bologna; Bologna Italy
| |
Collapse
|
44
|
Murawski N, Amam J, Altmann B, Ziepert M, Haenel M, Viardot A, Neubauer A, Held G, Truemper L, Dreyling M, Kanz L, Hallek M, Schmitz N, Heintges T, Koelbel C, Poeschel V, Pfreundschuh M. ANTI-INFECTIVE PROPHYLAXIS WITH ACICLOVIR AND COTRIMOXAZOLE SIGNIFICANTLY REDUCES THE RATE OF INFECTIONS AND THERAPY-ASSOCIATED DEATHS IN ELDERLY PATIENTS WITH DLBCL UNDERGOING R-CHOP IMMUNOCHEMOTHERAPY. Hematol Oncol 2017. [DOI: 10.1002/hon.2438_63] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- N. Murawski
- Hematology/Oncology; Saarland University Hospital; Homburg Germany
| | - J. Amam
- Hematology/Oncology; Saarland University Hospital; Homburg Germany
| | - B. Altmann
- IMISE; University of Leipzig; Leipzig Germany
| | - M. Ziepert
- IMISE; University of Leipzig; Leipzig Germany
| | - M. Haenel
- Internal Medicine III; Chemnitz Hospital; Chemnitz Germany
| | - A. Viardot
- Internal Medicine III; University Hospital Ulm; Ulm Germany
| | - A. Neubauer
- Hematology/Oncology; University Hospital Marburg; Marburg Germany
| | - G. Held
- Hematology/Oncology; Saarland University Hospital; Homburg Germany
| | - L. Truemper
- Department of Internal Medicine; University Hospital; Goettingen Germany
| | - M. Dreyling
- Department for Internal Medicine III; University Hospital Großhadern; Muenchen Germany
| | - L. Kanz
- Hematology/Oncology; University Hospital; Tuebingen Germany
| | - M. Hallek
- Internal Medicine I; University Hospital; Koeln Germany
| | - N. Schmitz
- Hematology, ASKLEPIOS clinic; Hamburg Germany
| | - T. Heintges
- Internal Medicine III, Lukaskrankenhaus; Neuss Germany
| | - C. Koelbel
- Internal Medicine I, Krankenhaus der Barmherzigen Brueder; Trier Germany
| | - V. Poeschel
- Hematology/Oncology; Saarland University Hospital; Homburg Germany
| | - M. Pfreundschuh
- Hematology/Oncology; Saarland University Hospital; Homburg Germany
| |
Collapse
|
45
|
Zinzani P, Dreyling M, Patnaik A, Morschhauser F, Benson A, Genvresse I, Miriyala A, Garcia-Vargas J, Childs B. INTEGRATED SAFETY DATA WITH COPANLISIB MONOTHERAPY FROM PHASE I AND II TRIALS IN PATIENTS WITH RELAPSED INDOLENT NON-HODGKIN'S LYMPHOMA. Hematol Oncol 2017. [DOI: 10.1002/hon.2438_141] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- P. Zinzani
- Department of Hematology; Institute of Hematology "L. e A. Seràgnoli"- University of Bologna; Bologna Italy
| | - M. Dreyling
- Medizinische Klinik und Poliklinik III; Klinikum der Universität München-Grosshadern; Munich Germany
| | - A. Patnaik
- Medical Oncology; South Texas Accelerated Research Therapeutics (START) Center for Cancer Care; San Antonio TX USA
| | - F. Morschhauser
- Department of Hematology; CHRU - Hôpital Claude Huriez; Lille France
| | - A. Benson
- Clinical Statistics; Bayer HealthCare Pharmaceuticals Inc; Whippany-NJ USA
| | - I. Genvresse
- Pharmaceutical Division, Bayer AG; Berlin Germany
| | - A. Miriyala
- Clinical Development; Bayer HealthCare Pharmaceuticals Inc; Whippany-NJ USA
| | - J. Garcia-Vargas
- Clinical Development; Bayer HealthCare Pharmaceuticals Inc; Whippany-NJ USA
| | - B.H. Childs
- Clinical Development; Bayer HealthCare Pharmaceuticals Inc; Whippany-NJ USA
| |
Collapse
|
46
|
Schöppe F, Sommer W, Dreyling M, Verbeek M, Westphalen C, Bogner C, Nörenberg D, Reiser M, Rummeny E, Fingerle A. Mehrwert der strukturierten Befundung bei CT-Untersuchungen im Rahmen des Primärstagings bei Patienten mit diffus großzelligem B-Zell-Lymphom. ROFO-FORTSCHR RONTG 2017. [DOI: 10.1055/s-0037-1600423] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
Affiliation(s)
- F Schöppe
- Klinikum der Universität München, Institut für Klinische Radiologie, München
| | - W Sommer
- Klinikum der Universität München, Institut für Klinische Radiologie, München
| | - M Dreyling
- Klinikum der Universität München, Medizinische Klinik und Poliklinik III, München
| | - M Verbeek
- Klinikum rechts der Isar der TU München, Klinik und Poliklinik für Innere Medizin III, Hämatologie und Onkologie, München
| | - C Westphalen
- Klinikum der Universität München, Medizinische Klinik und Poliklinik III, München
| | - C Bogner
- Klinikum rechts der Isar der TU München, Klinik und Poliklinik für Innere Medizin III, Hämatologie und Onkologie, München
| | - D Nörenberg
- Klinikum der Universität München, Institut für Klinische Radiologie, München
| | - M Reiser
- Klinikum der Universität München, Institut für Klinische Radiologie, München
| | - E Rummeny
- Klinikum rechts der Isar der TU München, Institut für diagnostische und interventionelle Radiologie, München
| | - A Fingerle
- Klinikum rechts der Isar der TU München, Institut für diagnostische und interventionelle Radiologie, München
| |
Collapse
|
47
|
Ladetto M, Buske C, Hutchings M, Dreyling M, Gaidano G, Le Gouill S, Luminari S, Pott C, Zamò A, Zucca E. ESMO consensus conference on malignant lymphoma: general perspectives and recommendations for prognostic tools in mature B-cell lymphomas and chronic lymphocytic leukaemia. Ann Oncol 2016; 27:2149-2160. [PMID: 27701070 DOI: 10.1093/annonc/mdw419] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2016] [Revised: 08/11/2016] [Accepted: 08/23/2016] [Indexed: 01/02/2023] Open
Abstract
The European Society for Medical Oncology (ESMO) consensus conference on mature B-cell lymphomas and chronic lymphocytic leukaemia (CLL) was held on 20 June 2015 in Lugano, Switzerland, and included a multidisciplinary panel of 25 leading experts. The aim of the conference was to develop recommendations on critical subjects difficult to consider in detail in the ESMO Clinical Practice Guidelines. The following areas were identified: (i) the elderly patient, (ii) prognostic factors suitable for clinical use and (iii) the 'ultra-high-risk' group. Before the conference, the expert panel was divided into three working groups; each group focused on one of these areas in order to address four clinically relevant questions relating to that topic. All relevant scientific literature, as identified by the experts, was reviewed in advance. During the consensus conference, each working group developed recommendations to address each of the four questions assigned to their group. These recommendations were then presented to the entire panel and a consensus was reached. This manuscript presents recommendations dedicated to the second area of interest, i.e. prognostic factors suitable for clinical use. The four topics [i.e. interim positron emission tomography (PET), TP53 mutations, cell of origin (COO) and minimal residual disease (MRD)] were primarily chosen because of the bulk of available data together with the lack of clear guidance regarding their use in clinical practice and within clinical trials. Results, including a summary of evidence supporting each recommendation, are detailed in this manuscript. The panel acknowledged that detection of TP53 inactivation by deletion or mutation in CLL should be implemented in clinical practice (level of evidence I, strength of recommendation A). Due to their potentially high prognostic value, at least in some lymphoma entities, implementation of interim PET, COO and MRD was highly recommended in the context of clinical trials. All expert panel members approved this final article.
Collapse
Affiliation(s)
- M Ladetto
- Hematology Division, Azienda Ospedaliera Santi Antonio e Biagio e Cesare Arrigo, Alessandria, Italy
| | - C Buske
- Comprehensive Cancer Center Ulm and Department of Internal Medicine III, Institute of Experimental Cancer Research, University Hospital, Ulm, Germany
| | - M Hutchings
- Department of Hematology, Rigshospitalet, Copenhagen, Denmark
| | - M Dreyling
- Medizinische Klinik III, Klinikum der Universität München/LMU, Munich, Germany
| | - G Gaidano
- Division of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy
| | - S Le Gouill
- Clinical Hematology, Centre Hospitalo-Universitaire de Nantes, UMR892 Team 10, CIC Nantes, France
| | - S Luminari
- Hematology, Arcispedale S. Maria Nuova, IRCCS Reggio Emilia.,Department of Diagnostic, Clinical and Public Health Medicine, University of Modena and Reggio Emilia, Modena, Italy
| | - C Pott
- Second Medical Department, University Hospital Schleswig-Holstein, Kiel, Germany
| | - A Zamò
- Department of Diagnostics and Public Health, University of Verona, Verona, Italy
| | - E Zucca
- Lymphoma Unit, Oncology Institute of Southern Switzerland, Ospedale San Giovanni, Bellinzona, Switzerland
| | | |
Collapse
|
48
|
Dreyling M, Krekeler G, Neuhof A, Woike M, Hess G, Kalanovic D. Evaluation of safety, tolerability and efficacy of temsirolimus in patients (pts) with relapsed or refractory mantle cell lymphoma (rel/refr MCL) in routine clinical practice. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw375.25] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
49
|
Koch K, Hoster E, Ziepert M, Unterhalt M, Ott G, Rosenwald A, Hansmann M, Bernd W, Stein H, Pöschel V, Dreyling M, Trümper L, Löffler M, Schmitz N, Hiddemann W, Pfreundschuh M, Klapper W. Clinical, pathological and genetic features of follicular lymphoma grade 3A: a joint analysis of the German low-grade and high-grade lymphoma study groups GLSG and DSHNHL. Ann Oncol 2016; 27:1323-9. [DOI: 10.1093/annonc/mdw185] [Citation(s) in RCA: 41] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/14/2016] [Accepted: 04/22/2016] [Indexed: 11/14/2022] Open
|
50
|
Leich E, Hoster E, Wartenberg M, Unterhalt M, Siebert R, Koch K, Klapper W, Engelhard M, Puppe B, Horn H, Staiger AM, Stuhlmann-Laeisz C, Bernd HW, Feller AC, Hummel M, Lenze D, Stein H, Hartmann S, Hansmann ML, Möller P, Hiddemann W, Dreyling M, Ott G, Rosenwald A. Similar clinical features in follicular lymphomas with and without breaks in the BCL2 locus. Leukemia 2015; 30:854-60. [PMID: 26621338 DOI: 10.1038/leu.2015.330] [Citation(s) in RCA: 32] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/29/2015] [Revised: 11/05/2015] [Accepted: 11/13/2015] [Indexed: 01/18/2023]
Abstract
Approximately 15% of follicular lymphomas (FLs) lack breaks in the BCL2 locus. The aim of this study was to better define molecular and clinical features of BCL2-breakpoint/t(14;18)-negative FLs. We studied the presence of BCL2, BCL6 and MYC breaks by fluorescence in situ hybridization and the expression of BCL2, MUM1, CD10, P53 and Ki67 in large clinical trial cohorts of 540 advanced-stage FL cases and 116 early-stage disease FL patients treated with chemotherapy regimens and radiation, respectively. A total of 86% and 53% of advanced- and early-stage FLs were BCL2-breakpoint-positive, respectively. BCL2 was expressed in almost all FLs with BCL2 break and also in 86% and 69% of BCL2-breakpoint-negative advanced- and early-stage FLs, respectively. CD10 expression was significantly reduced in BCL2-breakpoint-negative FLs of all stages and MUM1 and Ki67 expression were significantly increased in BCL2-break-negative early-stage FLs. Patient characteristics did not differ between FLs with and without BCL2 breaks and neither did survival times in advanced-stage FLs. These results suggest that the molecular profile differs to some extent between FLs with and without BCL2 breaks and support the notion that FLs with and without BCL2 breaks belong to the same lymphoma entity.
Collapse
Affiliation(s)
- E Leich
- Institute of Pathology, University of Würzburg, Würzburg, Germany.,Comprehensive Cancer Center Mainfranken (CCC MF), Würzburg, Germany
| | - E Hoster
- Institute of Medical Informatics, Biometry, and Epidemiology, University of Munich, Munich, Germany
| | - M Wartenberg
- Institute of Pathology, University of Würzburg, Würzburg, Germany.,Comprehensive Cancer Center Mainfranken (CCC MF), Würzburg, Germany
| | - M Unterhalt
- Department of Internal Medicine III, University Hospital Munich, Munich, Germany
| | - R Siebert
- Institute of Human Genetics, Christian-Albrechts-University Kiel and University Hospital Schleswig-Holstein, Kiel, Germany
| | - K Koch
- Institute of Pathology, Hematopathology Section and Lymph Node Registry, University Hospital Schleswig-Holstein, Kiel, Germany
| | - W Klapper
- Institute of Pathology, Hematopathology Section and Lymph Node Registry, University Hospital Schleswig-Holstein, Kiel, Germany
| | - M Engelhard
- Department for Radiotherapy, University Hospital Essen, Essen, Germany
| | - B Puppe
- Institute of Pathology, University of Würzburg, Würzburg, Germany.,Comprehensive Cancer Center Mainfranken (CCC MF), Würzburg, Germany
| | - H Horn
- Margarete Fischer-Bosch Institute of Clinical Pharmacology, Robert-Bosch-Krankenhaus, Stuttgart and University of Tübingen, Tübingen, Germany
| | - A M Staiger
- Margarete Fischer-Bosch Institute of Clinical Pharmacology, Robert-Bosch-Krankenhaus, Stuttgart and University of Tübingen, Tübingen, Germany
| | - C Stuhlmann-Laeisz
- Institute of Human Genetics, Christian-Albrechts-University Kiel and University Hospital Schleswig-Holstein, Kiel, Germany
| | - H W Bernd
- Institute of Pathology, University Hospital Schleswig-Holstein, Lübeck, Germany
| | - A C Feller
- Institute of Pathology, University Hospital Schleswig-Holstein, Lübeck, Germany
| | - M Hummel
- Institute of Pathology, Campus Benjamin Franklin, Charité Universitätsmedizin, Berlin, Germany
| | - D Lenze
- Institute of Pathology, Campus Benjamin Franklin, Charité Universitätsmedizin, Berlin, Germany
| | - H Stein
- Pathodiagnostik Berlin, Berlin, Germany
| | - S Hartmann
- Institute of Pathology, University Hospital Frankfurt am, Frankfurt, Germany
| | - M L Hansmann
- Institute of Pathology, University Hospital Frankfurt am, Frankfurt, Germany
| | - P Möller
- Institute of Pathology, University Hospital Ulm, Ulm, Germany
| | - W Hiddemann
- Department of Internal Medicine III, University Hospital Munich, Munich, Germany
| | - M Dreyling
- Department of Internal Medicine III, University Hospital Munich, Munich, Germany
| | - G Ott
- Department of Clinical Pathology, Robert-Bosch-Krankenhaus, Stuttgart, Germany
| | - A Rosenwald
- Institute of Pathology, University of Würzburg, Würzburg, Germany.,Comprehensive Cancer Center Mainfranken (CCC MF), Würzburg, Germany
| | | |
Collapse
|